{"custom_id": "alendronic acid-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Lamivudine"}]}}
{"custom_id": "Gabapentin-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-erythema-Ibuprofen"}]}}
{"custom_id": "Duloxetine-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-apoplexy-Sorafenib"}]}}
{"custom_id": "Gabapentin-Palonosetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Palonosetron\nDRUG 2 BACKGROUND INFORMATION: Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.\nPalonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than  other 5-HT3 antagonists. The oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. It is on the World Health Organization's List of Essential Medicines.\nThe oral combination netupitant/palonosetron is approved for both acute and delayed CINV.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-drug toxicity NOS-Palonosetron"}]}}
{"custom_id": "Methylphenidate-Etiracetam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Etiracetam\nDRUG 2 BACKGROUND INFORMATION: Etiracetam is a chemical compound belonging to the racetam family, which was developed as a nootropic drug. It is racemic; its biologically active enantiomeric form is levetiracetam, now marketed as an antiepileptic drug.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-abnormal EEG-Etiracetam"}]}}
{"custom_id": "Fentanyl-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-gastric inflammation-vincristine"}]}}
{"custom_id": "Furosemide-melphalan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: melphalan\nDRUG 2 BACKGROUND INFORMATION: Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.\nCommon side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.\nMelphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-Dyspnea exertional-melphalan"}]}}
{"custom_id": "Diazepam-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-Sinus headache-Imatinib"}]}}
{"custom_id": "Cetirizine-Moexipril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Moexipril\nDRUG 2 BACKGROUND INFORMATION: Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. \nIt works by inhibiting the conversion of angiotensin I to angiotensin II. \nIt was patented in 1980 and approved for medical use in 1995. Moexipril is available from Schwarz Pharma under the trade name Univasc.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-High blood pressure-Moexipril"}]}}
{"custom_id": "Naproxen-Ondansetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Dyspnea exertional-Ondansetron"}]}}
{"custom_id": "Amlodipine-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-acute pancreatitis-Propofol"}]}}
{"custom_id": "Famotidine-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-right heart failure-Metolazone"}]}}
{"custom_id": "Lidocaine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lidocaine-erythema-Torasemide"}]}}
{"custom_id": "Candesartan-Fenofibrate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Fenofibrate\nDRUG 2 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-gastric inflammation-Fenofibrate"}]}}
{"custom_id": "Gabapentin-Tramadol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Tramadol\nDRUG 2 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-cholecystitis-Tramadol"}]}}
{"custom_id": "Cetirizine-Temozolomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Temozolomide\nDRUG 2 BACKGROUND INFORMATION: Temozolomide is a cytotoxic alkylating agent employed primarily in neuro-oncology for the management of high-grade gliomas, including glioblastoma multiforme and anaplastic astrocytoma, administered orally or intravenously. The therapeutic action involves DNA methylation at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis, particularly effective in the presence of MGMT promoter methylation, enhancing chemosensitivity. Adverse hematologic effects largely manifest as myelosuppression, including neutropenia, lymphopenia, and thrombocytopenia, alongside gastrointestinal disturbances such as emesis and anorexia, dermatological reactions typified by alopecia and rash, and neurological symptoms like convulsions and fatigue. Additionally, temozolomide's synergistic efficacy with PARP inhibitors, notably olaparib, extends its utility in salvage therapy for recalcitrant malignancies like relapsed small cell lung cancer, augmenting its strategic application in oncology pharmacotherapy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-erythema-Temozolomide"}]}}
{"custom_id": "Diazepam-Ofloxacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Ofloxacin\nDRUG 2 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-gastric inflammation-Ofloxacin"}]}}
{"custom_id": "Citalopram-Fenofibrate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Fenofibrate\nDRUG 2 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fenofibrate"}]}}
{"custom_id": "Zolpidem-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zolpidem\nDRUG 1 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zolpidem-abnormal ECG-Bimatoprost"}]}}
{"custom_id": "Ketoprofen-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-gastric inflammation-oxybutynin"}]}}
{"custom_id": "Gabapentin-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-gastric inflammation-Terazosin"}]}}
{"custom_id": "Risedronic acid-Amiloride-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Amiloride\nDRUG 2 BACKGROUND INFORMATION: Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-elevated cholesterol-Amiloride"}]}}
{"custom_id": "Citalopram-Fluphenazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Fluphenazine\nDRUG 2 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine"}]}}
{"custom_id": "Telmisartan-Cinacalcet-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Telmisartan\nDRUG 1 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG 2 NAME: Cinacalcet\nDRUG 2 BACKGROUND INFORMATION: Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.\nThe most common side effects include nausea and vomiting.\nCinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Telmisartan-dysarthria-Cinacalcet"}]}}
{"custom_id": "Fluorouracil-mitomycin C-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fluorouracil\nDRUG 1 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG 2 NAME: mitomycin C\nDRUG 2 BACKGROUND INFORMATION: Mitomycin C is a mitomycin that is used as a  chemotherapeutic agent by virtue of its antitumour activity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fluorouracil-myelodysplasia-mitomycin C"}]}}
{"custom_id": "Diazepam-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-weight gain-desvenlafaxine"}]}}
{"custom_id": "Paracetamol-Midodrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Paracetamol\nDRUG 1 BACKGROUND INFORMATION: Paracetamol, or acetaminophen, functions as a para-aminophenol derivative providing analgesic and antipyretic effects predominantly by inhibiting COX enzymes within the central nervous system; however, its peripheral anti-inflammatory impact is minimal compared to nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. It is therapeutically advantageous for alleviating mild to moderate pain in conditions such as acute mild migraine and episodic tension headaches, though the analgesic efficacy is modest in osteoarthritic and low back pain contexts, with negligible evidence supporting its utility in cancer and neuropathic pain management. Paracetamol at standard dosing mitigates fever to a limited extent; however, it is suboptimal compared to ibuprofen, particularly in febrile states of viral etiology, rendering its role in antipyresis debatable. Despite its generally safe profile when administered short-term and adherence to a maximum recommended dosage of three to four grams daily, paracetamol harbors hepatotoxic potential when overdosed, being a preeminent cause of drug-induced acute hepatic failure in Western populations. Its metabolic pathway in the liver, involving cytochrome P450 enzymes and subsequent depletion of glutathione reserves, underscores the mechanism of hepatotoxicity. Chronic use may elicit gastrointestinal bleeding and hepatic dysfunction, whereas its utilization might be beneficial for patients contraindicated for NSAID therapy. Clinically, combination therapies, such as with ibuprofen, exhibit increased analgesic efficacy, while the triple combination of aspirin, paracetamol, and caffeine remains a preferred first-line intervention for mild pain syndromes. Paracetamol\u2019s clinical application persists widely, inscribed on the World Health Organization's List of Essential Medicines, and forecasts substantial prescription numbers globally.\n\nDRUG 2 NAME: Midodrine\nDRUG 2 BACKGROUND INFORMATION: Midodrine, sold under the brand names ProAmatine and Orvaten among others, is an antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence. It is taken by mouth.\nSide effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. Midodrine is a prodrug of its active metabolite desglymidodrine. This metabolite acts as a selective agonist of the \u03b11-adrenergic receptor. This in turn results in vasoconstriction and increased blood pressure.\nMidodrine was discovered by 1971 and was introduced for medical use in the United States in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Paracetamol-haematoma-Midodrine"}]}}
{"custom_id": "Citalopram-Isoniazid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Isoniazid\nDRUG 2 BACKGROUND INFORMATION: Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-angiitis-Isoniazid"}]}}
{"custom_id": "Candesartan-mitomycin C-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: mitomycin C\nDRUG 2 BACKGROUND INFORMATION: Mitomycin C is a mitomycin that is used as a  chemotherapeutic agent by virtue of its antitumour activity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-arterial pressure NOS increased-mitomycin C"}]}}
{"custom_id": "indometacin-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-Acute Respiratory Distress Syndrome-vincristine"}]}}
{"custom_id": "Methylphenidate-Metronidazole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Metronidazole\nDRUG 2 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-subarachnoid haemorrhage-Metronidazole"}]}}
{"custom_id": "Ondansetron-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-loss of weight-Pirbuterol"}]}}
{"custom_id": "Rofecoxib-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-cholecystitis-Trazodone"}]}}
{"custom_id": "Cimetidine-Citalopram-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram"}]}}
{"custom_id": "Ketorolac-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-apoplexy-oxybutynin"}]}}
{"custom_id": "Dapsone-Pyrimethamine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dapsone\nDRUG 1 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 2 NAME: Pyrimethamine\nDRUG 2 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine"}]}}
{"custom_id": "Ibuprofen-Balsalazide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Balsalazide\nDRUG 2 BACKGROUND INFORMATION: Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.\nIt is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. It is in the category of disease-modifying antirheumatic drugs (DMARDs) family of medications. It is unclear exactly how it works.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-belching-Balsalazide"}]}}
{"custom_id": "Diazepam-Pyridostigmine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-Diplopia-Pyridostigmine"}]}}
{"custom_id": "Cetirizine-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-elevated erythrocyte sedimentation rate-Terazosin"}]}}
{"custom_id": "Aciclovir-Emtricitabine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Emtricitabine\nDRUG 2 BACKGROUND INFORMATION: Emtricitabine (FTC; 2',3'-dideoxy-5-fluoro-3'-thiacytidine) operates as a potent nucleoside reverse-transcriptase inhibitor (NRTI) indicated for both prophylaxis and active management of HIV infection across diverse age cohorts. This molecule is integral to the composition of the Quad pill, specifically Stribild and Genvoya, and is prominently featured in fixed-dose co-formulations with tenofovir disoproxil as Truvada and with tenofovir alafenamide as Descovy, underscoring its critical role in multi-drug regimens. Emtricitabine's strategic inclusion in these combinations has earned it placement on the WHO's List of Essential Medicines, reflecting its indispensable utility in comprehensive antiretroviral therapy. Notably, the FDA-approved fixed-dose triple combination incorporating emtricitabine, tenofovir, and efavirenz, commercially available as Atripla, exemplifies its integration into optimized antiretroviral protocols aimed at maximizing therapeutic efficacy and medication adherence.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-Adenopathy-Emtricitabine"}]}}
{"custom_id": "Ondansetron-Pimecrolimus-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Pimecrolimus\nDRUG 2 BACKGROUND INFORMATION: Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). \nIt is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-weight gain-Pimecrolimus"}]}}
{"custom_id": "Amlodipine-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-apoplexy-Rosiglitazone"}]}}
{"custom_id": "Alprazolam-Bumetanide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Bumetanide\nDRUG 2 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-erythema-Bumetanide"}]}}
{"custom_id": "Lamotrigine-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-still birth-Metolazone"}]}}
{"custom_id": "Famotidine-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Trimethoprim"}]}}
{"custom_id": "Furosemide-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-loss of weight-desvenlafaxine"}]}}
{"custom_id": "Alprazolam-Sibutramine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Sibutramine\nDRUG 2 BACKGROUND INFORMATION: Sibutramine, a pharmacological intervention formerly indicated for obesity management, operates through its mechanism as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), akin to certain antidepressant modalities, modulating monoamine neurotransmitter pathways to exert anorectic effects. Despite its initial widespread utilization, it was contraindicated due to a correlation with augmented cardiovascular morbidity and cerebrovascular incidents, prompting market withdrawal across multiple jurisdictions including Australia, the European Union, and the United States by 2010. Developed by Boots Pharmaceuticals and subsequently commercialized by Abbott Laboratories under trade names such as Meridia and Reductil, sibutramine was a Schedule IV controlled entity in the United States before its discontinuation. However, the compound persists in unregulated domains, as evidenced by FDA findings of its presence in numerous purported \"natural\" or \"herbal\" supplements as recently as 2018, underscoring challenges in illicit pharmacovigilance.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Sibutramine"}]}}
{"custom_id": "Doxazosin-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-Hypoventilation-Darunavir"}]}}
{"custom_id": "Doxazosin-Formoterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Formoterol\nDRUG 2 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-aortic aneurysm-Formoterol"}]}}
{"custom_id": "Aciclovir-Lidocaine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Lidocaine"}]}}
{"custom_id": "Zafirlukast-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zafirlukast\nDRUG 1 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-weight gain-Rosiglitazone"}]}}
{"custom_id": "Tramadol-Ziprasidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tramadol-erythema-Ziprasidone"}]}}
{"custom_id": "Bumetanide-Ranolazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Bumetanide\nDRUG 1 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG 2 NAME: Ranolazine\nDRUG 2 BACKGROUND INFORMATION: Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.\nCommon side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.\nRanolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Bumetanide-apoplexy-Ranolazine"}]}}
{"custom_id": "Alprazolam-Lidocaine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-right heart failure-Lidocaine"}]}}
{"custom_id": "Naproxen-Minoxidil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Minoxidil\nDRUG 2 BACKGROUND INFORMATION: Minoxidil  is a medication used for the treatment of high blood pressure and pattern hair loss. It is an antihypertensive and a vasodilator. It is available as a generic medication by prescription in oral tablet form and over-the-counter as a topical liquid or foam.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastroenteritis viral-Minoxidil"}]}}
{"custom_id": "Fentanyl-Dobutamine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Dobutamine\nDRUG 2 BACKGROUND INFORMATION: Dobutamine, administered intravenously or intraosseously, is an adrenergic agonist specifically targeting \u03b21-adrenergic receptors, eliciting a pronounced inotropic response without significant chronotropic impact, thereby enhancing myocardial contractility and systemic perfusion in the management of cardiogenic shock and severe heart failure. The pharmacokinetics of dobutamine are characterized by rapid onset within two minutes and an elimination half-life of two minutes, necessitating titration to effect and favoring short-term administration, although it may be employed in extended durations in the context of pre-transplant heart failure symptomatology management. Adverse reactions primarily include tachyarrhythmias, injection site reactions, and contraindication in hypertrophic subaortic stenosis. Synthetically derived from isoproterenol, dobutamine has been devoid of significant chronotropic effects, making it distinct among inotropes.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-hypermagnesemia-Dobutamine"}]}}
{"custom_id": "Cimetidine-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-bursitis-Duloxetine"}]}}
{"custom_id": "Orphenadrine-Sumatriptan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Orphenadrine\nDRUG 1 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 2 NAME: Sumatriptan\nDRUG 2 BACKGROUND INFORMATION: Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-erythema-Sumatriptan"}]}}
{"custom_id": "Alprazolam-Indapamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Indapamide\nDRUG 2 BACKGROUND INFORMATION: Indapamide, a thiazide-like sulfonamide diuretic, is employed primarily in mitigating hypertension and addressing decompensated heart failure, functioning by inhibiting sodium reabsorption at the distal convoluted tubule, which consequently enhances renal excretion of sodium and water, thereby reducing plasma volume and vascular resistance. Its efficacy parallels that of traditional thiazide diuretics and, in combination with perindopril, exerts an enhanced antihypertensive synergy. Indapamide demonstrates a favorable cardiovascular profile, attenuating risks associated with major events and heart failure in hypertensive cohorts, akin to chlorthalidone, and shows superior outcomes compared to hydrochlorothiazide. Moreover, both thiazide and thiazide-like diuretics effectively minimize stroke incidence, maintaining safety profiles comparable to other antihypertensive classes such as angiotensin II receptor antagonists and dihydropyridine calcium antagonists, while exhibiting a diminished spectrum of adverse effects relative to ACE inhibitors and non-dihydropyridine calcium blockers, thus occupying a critical niche in essential therapeutic regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Indapamide"}]}}
{"custom_id": "Aciclovir-Dapsone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Dapsone"}]}}
{"custom_id": "Furosemide-Lamotrigine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-weight gain-Lamotrigine"}]}}
{"custom_id": "Aciclovir-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-myelodysplasia-Pamidronic acid"}]}}
{"custom_id": "Megestrol-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Megestrol\nDRUG 1 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Megestrol-cholecystitis-Duloxetine"}]}}
{"custom_id": "Ranitidine-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-cholecystitis-Thalidomide"}]}}
{"custom_id": "Ranitidine-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Fosphenytoin\nDRUG 2 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-agitated-Fosphenytoin"}]}}
{"custom_id": "Alprazolam-Gemfibrozil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Gemfibrozil"}]}}
{"custom_id": "Etiracetam-Erlotinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Etiracetam\nDRUG 1 BACKGROUND INFORMATION: Etiracetam is a chemical compound belonging to the racetam family, which was developed as a nootropic drug. It is racemic; its biologically active enantiomeric form is levetiracetam, now marketed as an antiepileptic drug.\n\nDRUG 2 NAME: Erlotinib\nDRUG 2 BACKGROUND INFORMATION: Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.\nCommon side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).\nErlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Etiracetam-dysarthria-Erlotinib"}]}}
{"custom_id": "Amphetamine-Modafinil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amphetamine\nDRUG 1 BACKGROUND INFORMATION: Amphetamine (alpha-methylphenethylamine), a prototypical phenethylamine and substituted amphetamine, acts as a potent central nervous system (CNS) stimulant, primarily augmenting norepinephrine and dopamine neurotransmission. It exists as racemic mixtures of its enantiomers, dextroamphetamine and levoamphetamine, used therapeutically in attention deficit hyperactivity disorder (ADHD), narcolepsy, and as lisdexamfetamine for binge eating disorder. Its sympathomimetic effects at prescribed doses manifest as euphoria, heightened alertness, cognitive enhancement, and anorectic effects, whereas supratherapeutic dosing can precipitate neurotoxicological outcomes such as dopamine dysregulation, leading to hallucinations, delusions, and sympathomimetic toxicity, including rhabdomyolysis. The pharmacodynamics involve promoting synaptic release and inhibiting reuptake of monoamines. Structurally related to endogenous trace amines like phenethylamine and N-methylphenethylamine, amphetamine has a notable abuse potential with illicit use often exceeding therapeutic dosages, thereby enhancing risk of addiction and psychosis. Historically, its derivatives have included drugs like bupropion, cathinone, MDMA, and methamphetamine, sharing mechanistic overlap in monoaminergic modulation. Therapeutically, amphetamine is available as racemic mixtures or as stereospecific formulations such as Adderall and dextroamphetamine, with its clinical applications intricately regulated given its high potential for misuse.\n\nDRUG 2 NAME: Modafinil\nDRUG 2 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amphetamine-apoplexy-Modafinil"}]}}
{"custom_id": "Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Pamidronic acid\nDRUG 1 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 2 NAME: thiotepa\nDRUG 2 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa"}]}}
{"custom_id": "Naproxen-alendronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: alendronic acid\nDRUG 2 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-alendronic acid"}]}}
{"custom_id": "Carvedilol-Efavirenz-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-High blood pressure-Efavirenz"}]}}
{"custom_id": "Carvedilol-Dobutamine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Dobutamine\nDRUG 2 BACKGROUND INFORMATION: Dobutamine, administered intravenously or intraosseously, is an adrenergic agonist specifically targeting \u03b21-adrenergic receptors, eliciting a pronounced inotropic response without significant chronotropic impact, thereby enhancing myocardial contractility and systemic perfusion in the management of cardiogenic shock and severe heart failure. The pharmacokinetics of dobutamine are characterized by rapid onset within two minutes and an elimination half-life of two minutes, necessitating titration to effect and favoring short-term administration, although it may be employed in extended durations in the context of pre-transplant heart failure symptomatology management. Adverse reactions primarily include tachyarrhythmias, injection site reactions, and contraindication in hypertrophic subaortic stenosis. Synthetically derived from isoproterenol, dobutamine has been devoid of significant chronotropic effects, making it distinct among inotropes.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-hepatitis-Dobutamine"}]}}
{"custom_id": "chlortalidone-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: chlortalidone\nDRUG 1 BACKGROUND INFORMATION: Chlortalidone, a thiazide-like sulfonamide diuretic, is predominantly prescribed for antihypertensive therapy and states of edema associated with heart failure, hepatic cirrhosis, and nephrotic syndrome, as well as for managing nephrogenic diabetes insipidus and renal tubular acidosis. Its pharmacodynamic efficacy stems from modulating renal sodium and water excretion, thereby affecting volume and pressure homeostasis; the precise mechanistic pathways, however, remain partially elucidated. Its pharmacokinetic profile reveals oral bioavailability with an onset of diuresis within approximately three hours, sustaining therapeutic effects for up to 72 hours. Comparative studies suggest chlortalidone's superior cardiovascular outcome efficacy over hydrochlorothiazide in long-term stroke and myocardial infarction prophylaxis, despite a contentious spectrum of adverse effect profiles, including hypokalemia, hyponatremia, hyperglycemia, orthostatic hypotension, and reduced erectile function, alongside rarer occurrences of gout, hypomagnesemia, hypercalcemia, and hypersensitivity reactions. Pregnancy use, although possible, is approached with caution due to alternative preferred therapeutics. As part of the WHO's essential medicines list, chlortalidone remains a critical agent in hypertension management, widely available as a cost-effective generic, reflecting its substantial utilization in clinical practice.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): chlortalidone-loss of weight-Sildenafil"}]}}
{"custom_id": "Ibuprofen-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol"}]}}
{"custom_id": "Candesartan-Citalopram-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-myelodysplasia-Citalopram"}]}}
{"custom_id": "Ibuprofen-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-bleeding Vaginal-desvenlafaxine"}]}}
{"custom_id": "Ziprasidone-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ziprasidone\nDRUG 1 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine"}]}}
{"custom_id": "indometacin-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-Back Ache-Salmeterol"}]}}
{"custom_id": "Lamotrigine-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-erythema-Salmeterol"}]}}
{"custom_id": "Gemfibrozil-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gemfibrozil\nDRUG 1 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gemfibrozil-erythema-Sildenafil"}]}}
{"custom_id": "alendronic acid-Pimecrolimus-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Pimecrolimus\nDRUG 2 BACKGROUND INFORMATION: Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). \nIt is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-nasopharyngitis-Pimecrolimus"}]}}
{"custom_id": "nevirapine-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: nevirapine\nDRUG 1 BACKGROUND INFORMATION: Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.\nCommon side effects include rash, headache, nausea, feeling tired, and liver problems. The liver problems and skin rash may be severe and should be checked for during the first few months of treatment. It appears to be safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.\nNevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): nevirapine-emesis-oxybutynin"}]}}
{"custom_id": "Aciclovir-Doxazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Doxazosin"}]}}
{"custom_id": "Diazepam-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-gastric inflammation-Duloxetine"}]}}
{"custom_id": "Famotidine-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Ticlopidine\nDRUG 2 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Extrasystoles Ventricular-Ticlopidine"}]}}
{"custom_id": "Alprazolam-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-apoplexy-Terazosin"}]}}
{"custom_id": "Amlodipine-Cinacalcet-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Cinacalcet\nDRUG 2 BACKGROUND INFORMATION: Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.\nThe most common side effects include nausea and vomiting.\nCinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-abnormal EEG-Cinacalcet"}]}}
{"custom_id": "Candesartan-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-gastric inflammation-Pamidronic acid"}]}}
{"custom_id": "alendronic acid-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Salmeterol"}]}}
{"custom_id": "alendronic acid-Alprazolam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Alprazolam\nDRUG 2 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Alprazolam"}]}}
{"custom_id": "Fentanyl-Nimodipine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Nimodipine\nDRUG 2 BACKGROUND INFORMATION: Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication. \nIt was patented in 1971 and approved for medical use in the United States in 1988. It was approved for medical use in Germany in 1985.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-muscle disorder-Nimodipine"}]}}
{"custom_id": "Aciclovir-Citalopram-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram"}]}}
{"custom_id": "Lidocaine-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lidocaine-trigeminal neuralgia-Pamidronic acid"}]}}
{"custom_id": "Triazolam-Exemestane-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Triazolam\nDRUG 1 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG 2 NAME: Exemestane\nDRUG 2 BACKGROUND INFORMATION: Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Triazolam-cholecystitis-Exemestane"}]}}
{"custom_id": "Efavirenz-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Efavirenz\nDRUG 1 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Efavirenz-constipated-oxybutynin"}]}}
{"custom_id": "Amlodipine-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-Adenopathy-Dexpramipexole"}]}}
{"custom_id": "Amlodipine-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-erythema-Thalidomide"}]}}
{"custom_id": "Naproxen-Temazepam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Acne-Temazepam"}]}}
{"custom_id": "Diazepam-Formoterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Formoterol\nDRUG 2 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-loss of weight-Formoterol"}]}}
{"custom_id": "Ranitidine-gadoversetamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: gadoversetamide\nDRUG 2 BACKGROUND INFORMATION: Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver. It is marketed under the trade name OptiMARK.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-bulging-gadoversetamide"}]}}
{"custom_id": "Naproxen-Lamotrigine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine"}]}}
{"custom_id": "Carvedilol-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-gastric inflammation-Dexpramipexole"}]}}
{"custom_id": "phenytoin-Dapsone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: phenytoin\nDRUG 1 BACKGROUND INFORMATION: Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): phenytoin-haemorrhage intracranial-Dapsone"}]}}
{"custom_id": "Celecoxib-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-icterus-Propofol"}]}}
{"custom_id": "Gabapentin-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-Adenopathy-Lamivudine"}]}}
{"custom_id": "Norfloxacin-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Norfloxacin\nDRUG 1 BACKGROUND INFORMATION: Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.\nNorfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.\nIt was patented in 1977 and approved for medical use in 1983.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Norfloxacin-confusion-Sorafenib"}]}}
{"custom_id": "Candesartan-Famotidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-excessive thirst-Famotidine"}]}}
{"custom_id": "Rofecoxib-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-Adenopathy-Zolpidem"}]}}
{"custom_id": "Modafinil-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Modafinil\nDRUG 1 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Modafinil-High blood pressure-Pamidronic acid"}]}}
{"custom_id": "Fluorouracil-Indapamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fluorouracil\nDRUG 1 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG 2 NAME: Indapamide\nDRUG 2 BACKGROUND INFORMATION: Indapamide, a thiazide-like sulfonamide diuretic, is employed primarily in mitigating hypertension and addressing decompensated heart failure, functioning by inhibiting sodium reabsorption at the distal convoluted tubule, which consequently enhances renal excretion of sodium and water, thereby reducing plasma volume and vascular resistance. Its efficacy parallels that of traditional thiazide diuretics and, in combination with perindopril, exerts an enhanced antihypertensive synergy. Indapamide demonstrates a favorable cardiovascular profile, attenuating risks associated with major events and heart failure in hypertensive cohorts, akin to chlorthalidone, and shows superior outcomes compared to hydrochlorothiazide. Moreover, both thiazide and thiazide-like diuretics effectively minimize stroke incidence, maintaining safety profiles comparable to other antihypertensive classes such as angiotensin II receptor antagonists and dihydropyridine calcium antagonists, while exhibiting a diminished spectrum of adverse effects relative to ACE inhibitors and non-dihydropyridine calcium blockers, thus occupying a critical niche in essential therapeutic regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fluorouracil-cellulitis-Indapamide"}]}}
{"custom_id": "Carvedilol-Pilocarpine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Pilocarpine\nDRUG 2 BACKGROUND INFORMATION: Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-fracture nonunion-Pilocarpine"}]}}
{"custom_id": "Ondansetron-Telmisartan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-apoplexy-Telmisartan"}]}}
{"custom_id": "Celecoxib-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-loss of weight-Pirbuterol"}]}}
{"custom_id": "Furosemide-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-amyloidosis-vincristine"}]}}
{"custom_id": "Carvedilol-Famotidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-Cardiomyopathy-Famotidine"}]}}
{"custom_id": "Candesartan-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-Back Ache-Thalidomide"}]}}
{"custom_id": "Gabapentin-Ziprasidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-loss of weight-Ziprasidone"}]}}
{"custom_id": "Citalopram-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-gastric inflammation-Terazosin"}]}}
{"custom_id": "Zolpidem-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zolpidem\nDRUG 1 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-solifenacin"}]}}
{"custom_id": "Rofecoxib-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-cholecystitis-Torasemide"}]}}
{"custom_id": "Celecoxib-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-cholecystitis-Desloratadine"}]}}
{"custom_id": "Methylphenidate-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-loss of weight-Salmeterol"}]}}
{"custom_id": "Metoprolol-Perphenazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metoprolol\nDRUG 1 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 2 NAME: Perphenazine\nDRUG 2 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine"}]}}
{"custom_id": "Lamotrigine-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-cholecystitis-oxybutynin"}]}}
{"custom_id": "acetazolamide-Celecoxib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Celecoxib\nDRUG 2 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Celecoxib"}]}}
{"custom_id": "Naproxen-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Back Ache-Torasemide"}]}}
{"custom_id": "Famotidine-Lamotrigine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamotrigine"}]}}
{"custom_id": "Cetirizine-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-Erythema nodosum-desvenlafaxine"}]}}
{"custom_id": "Duloxetine-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-Adenopathy-desvenlafaxine"}]}}
{"custom_id": "Celecoxib-Midodrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Midodrine\nDRUG 2 BACKGROUND INFORMATION: Midodrine, sold under the brand names ProAmatine and Orvaten among others, is an antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence. It is taken by mouth.\nSide effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. Midodrine is a prodrug of its active metabolite desglymidodrine. This metabolite acts as a selective agonist of the \u03b11-adrenergic receptor. This in turn results in vasoconstriction and increased blood pressure.\nMidodrine was discovered by 1971 and was introduced for medical use in the United States in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-allergic dermatitis-Midodrine"}]}}
{"custom_id": "Amlodipine-Furosemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Furosemide\nDRUG 2 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-metabolic encephalopathy-Furosemide"}]}}
{"custom_id": "oxybutynin-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: oxybutynin\nDRUG 1 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): oxybutynin-apoplexy-Zaleplon"}]}}
{"custom_id": "Celecoxib-tolcapone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: tolcapone\nDRUG 2 BACKGROUND INFORMATION: Tolcapone, sold under the brand name Tasmar, is a medication used to treat Parkinson's disease (PD).  It is a selective, potent and reversible nitrocatechol-type inhibitor of the enzyme catechol-O-methyltransferase (COMT). It has demonstrated significant liver toxicity, which has led to suspension of marketing authorisations in a number of countries.\nTolcapone appears to be peripherally selective, but can still cross into the brain in significant amounts and has been found to inhibit COMT centrally as well. In comparison with entacapone, another nitrocatechol COMT inhibitor, tolcapone has a longer half life (2.9 hours vs. 0.8 hours) and can better penetrate into the brain, acting both in the central nervous system and in the periphery. However, entacapone is less toxic for the liver.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-trigeminal neuralgia-tolcapone"}]}}
{"custom_id": "Temozolomide-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temozolomide\nDRUG 1 BACKGROUND INFORMATION: Temozolomide is a cytotoxic alkylating agent employed primarily in neuro-oncology for the management of high-grade gliomas, including glioblastoma multiforme and anaplastic astrocytoma, administered orally or intravenously. The therapeutic action involves DNA methylation at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis, particularly effective in the presence of MGMT promoter methylation, enhancing chemosensitivity. Adverse hematologic effects largely manifest as myelosuppression, including neutropenia, lymphopenia, and thrombocytopenia, alongside gastrointestinal disturbances such as emesis and anorexia, dermatological reactions typified by alopecia and rash, and neurological symptoms like convulsions and fatigue. Additionally, temozolomide's synergistic efficacy with PARP inhibitors, notably olaparib, extends its utility in salvage therapy for recalcitrant malignancies like relapsed small cell lung cancer, augmenting its strategic application in oncology pharmacotherapy.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temozolomide-gastric inflammation-Thalidomide"}]}}
{"custom_id": "Haloperidol-indometacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: indometacin\nDRUG 2 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Haloperidol-erythema multiforme-indometacin"}]}}
{"custom_id": "Amlodipine-Ziprasidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-loss of weight-Ziprasidone"}]}}
{"custom_id": "Citalopram-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-metabolic encephalopathy-Thalidomide"}]}}
{"custom_id": "Norfloxacin-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Norfloxacin\nDRUG 1 BACKGROUND INFORMATION: Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.\nNorfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.\nIt was patented in 1977 and approved for medical use in 1983.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Norfloxacin-folate deficiency-Zolpidem"}]}}
{"custom_id": "Naproxen-Furosemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Furosemide\nDRUG 2 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Furosemide"}]}}
{"custom_id": "Fentanyl-Labetalol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-back injury-Labetalol"}]}}
{"custom_id": "Temazepam-Cinacalcet-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Cinacalcet\nDRUG 2 BACKGROUND INFORMATION: Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.\nThe most common side effects include nausea and vomiting.\nCinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-constipated-Cinacalcet"}]}}
{"custom_id": "Ranitidine-Dobutamine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Dobutamine\nDRUG 2 BACKGROUND INFORMATION: Dobutamine, administered intravenously or intraosseously, is an adrenergic agonist specifically targeting \u03b21-adrenergic receptors, eliciting a pronounced inotropic response without significant chronotropic impact, thereby enhancing myocardial contractility and systemic perfusion in the management of cardiogenic shock and severe heart failure. The pharmacokinetics of dobutamine are characterized by rapid onset within two minutes and an elimination half-life of two minutes, necessitating titration to effect and favoring short-term administration, although it may be employed in extended durations in the context of pre-transplant heart failure symptomatology management. Adverse reactions primarily include tachyarrhythmias, injection site reactions, and contraindication in hypertrophic subaortic stenosis. Synthetically derived from isoproterenol, dobutamine has been devoid of significant chronotropic effects, making it distinct among inotropes.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-apoplexy-Dobutamine"}]}}
{"custom_id": "Ofloxacin-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ofloxacin\nDRUG 1 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-weight gain-Imatinib"}]}}
{"custom_id": "alendronic acid-Sumatriptan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Sumatriptan\nDRUG 2 BACKGROUND INFORMATION: Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Sumatriptan"}]}}
{"custom_id": "alendronic acid-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-gastric inflammation-Ibuprofen"}]}}
{"custom_id": "Naproxen-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-Terazosin"}]}}
{"custom_id": "Furosemide-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-gastric inflammation-Oxaprozin"}]}}
{"custom_id": "Naproxen-Amoxapine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Amoxapine\nDRUG 2 BACKGROUND INFORMATION: Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1980, approximately 10 to 20 years after most of the other TCAs were introduced in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-glaucoma-Amoxapine"}]}}
{"custom_id": "Etiracetam-Ziprasidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Etiracetam\nDRUG 1 BACKGROUND INFORMATION: Etiracetam is a chemical compound belonging to the racetam family, which was developed as a nootropic drug. It is racemic; its biologically active enantiomeric form is levetiracetam, now marketed as an antiepileptic drug.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Etiracetam-abnormal EEG-Ziprasidone"}]}}
{"custom_id": "Celecoxib-Chloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Chloroquine\nDRUG 2 BACKGROUND INFORMATION: Chloroquine, a 4-aminoquinoline class antiparasitic agent, primarily exerts its antimalarial effects by disrupting Plasmodium spp. asexual intraerythrocytic stages through the accumulation of toxic haem within the parasite's acidic food vacuoles, thus hindering haemozoin biocrystallization and ultimately leading to plasmodicidal activity. Resistance phenomena necessitate adjunctive or alternative therapeutics, particularly among certain Plasmodium falciparum isolates. Beyond malaria, chloroquine demonstrates efficacy in extra-intestinal amoebiasis and provides therapeutic benefit in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus, though the mechanistic pathways in these diseases remain elusive. Orally administered, chloroquine's adverse profile includes neuromuscular, dermatological, and gastrointestinal disturbances, with severe toxicities encompassing retinopathy, cardiomyopathy, and hematologic dyscrasias. Despite exploratory investigations during the COVID-19 pandemic, the NIH advises against its use due to inefficacious outcomes in controlled trials. Chloroquine's inclusion in the World Health Organization's compendium of essential medicines underscores its indispensable role in therapeutics, and its established genetic availability ensures widespread access.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-angiitis-Chloroquine"}]}}
{"custom_id": "Ranitidine-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-cholecystitis-Rosiglitazone"}]}}
{"custom_id": "acetazolamide-Famotidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Famotidine"}]}}
{"custom_id": "Ketorolac-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Ticlopidine\nDRUG 2 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-apoplexy-Ticlopidine"}]}}
{"custom_id": "Famotidine-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Fosphenytoin\nDRUG 2 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-erythema-Fosphenytoin"}]}}
{"custom_id": "Ranitidine-Sibutramine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Sibutramine\nDRUG 2 BACKGROUND INFORMATION: Sibutramine, a pharmacological intervention formerly indicated for obesity management, operates through its mechanism as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), akin to certain antidepressant modalities, modulating monoamine neurotransmitter pathways to exert anorectic effects. Despite its initial widespread utilization, it was contraindicated due to a correlation with augmented cardiovascular morbidity and cerebrovascular incidents, prompting market withdrawal across multiple jurisdictions including Australia, the European Union, and the United States by 2010. Developed by Boots Pharmaceuticals and subsequently commercialized by Abbott Laboratories under trade names such as Meridia and Reductil, sibutramine was a Schedule IV controlled entity in the United States before its discontinuation. However, the compound persists in unregulated domains, as evidenced by FDA findings of its presence in numerous purported \"natural\" or \"herbal\" supplements as recently as 2018, underscoring challenges in illicit pharmacovigilance.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-gastric inflammation-Sibutramine"}]}}
{"custom_id": "Furosemide-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-right heart failure-Salmeterol"}]}}
{"custom_id": "Metronidazole-Pimecrolimus-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Pimecrolimus\nDRUG 2 BACKGROUND INFORMATION: Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). \nIt is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-Adenopathy-Pimecrolimus"}]}}
{"custom_id": "Rofecoxib-Triazolam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Triazolam\nDRUG 2 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-cholecystitis-Triazolam"}]}}
{"custom_id": "acetazolamide-Diazepam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Diazepam\nDRUG 2 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Diazepam"}]}}
{"custom_id": "Methylphenidate-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-apoplexy-Sorafenib"}]}}
{"custom_id": "Citalopram-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-Adenopathy-Zolpidem"}]}}
{"custom_id": "Efavirenz-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Efavirenz\nDRUG 1 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Efavirenz-elevated cholesterol-Perindopril"}]}}
{"custom_id": "indometacin-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-apoplexy-oxybutynin"}]}}
{"custom_id": "Celecoxib-Palonosetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Palonosetron\nDRUG 2 BACKGROUND INFORMATION: Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.\nPalonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than  other 5-HT3 antagonists. The oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. It is on the World Health Organization's List of Essential Medicines.\nThe oral combination netupitant/palonosetron is approved for both acute and delayed CINV.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-cellulitis-Palonosetron"}]}}
{"custom_id": "Carvedilol-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-cholecystitis-Ibuprofen"}]}}
{"custom_id": "Candesartan-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-weight gain-Perindopril"}]}}
{"custom_id": "Methylphenidate-Ofloxacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Ofloxacin\nDRUG 2 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-drug toxicity NOS-Ofloxacin"}]}}
{"custom_id": "Rofecoxib-Etiracetam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Etiracetam\nDRUG 2 BACKGROUND INFORMATION: Etiracetam is a chemical compound belonging to the racetam family, which was developed as a nootropic drug. It is racemic; its biologically active enantiomeric form is levetiracetam, now marketed as an antiepileptic drug.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-Dyspnea exertional-Etiracetam"}]}}
{"custom_id": "Lidocaine-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lidocaine-enlarged liver-vincristine"}]}}
{"custom_id": "Minoxidil-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Minoxidil\nDRUG 1 BACKGROUND INFORMATION: Minoxidil  is a medication used for the treatment of high blood pressure and pattern hair loss. It is an antihypertensive and a vasodilator. It is available as a generic medication by prescription in oral tablet form and over-the-counter as a topical liquid or foam.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Minoxidil-thrombocytopenia-Perindopril"}]}}
{"custom_id": "Amlodipine-Pyridostigmine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-loss of weight-Pyridostigmine"}]}}
{"custom_id": "Cetirizine-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-Sinus headache-Imatinib"}]}}
{"custom_id": "alendronic acid-Indapamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Indapamide\nDRUG 2 BACKGROUND INFORMATION: Indapamide, a thiazide-like sulfonamide diuretic, is employed primarily in mitigating hypertension and addressing decompensated heart failure, functioning by inhibiting sodium reabsorption at the distal convoluted tubule, which consequently enhances renal excretion of sodium and water, thereby reducing plasma volume and vascular resistance. Its efficacy parallels that of traditional thiazide diuretics and, in combination with perindopril, exerts an enhanced antihypertensive synergy. Indapamide demonstrates a favorable cardiovascular profile, attenuating risks associated with major events and heart failure in hypertensive cohorts, akin to chlorthalidone, and shows superior outcomes compared to hydrochlorothiazide. Moreover, both thiazide and thiazide-like diuretics effectively minimize stroke incidence, maintaining safety profiles comparable to other antihypertensive classes such as angiotensin II receptor antagonists and dihydropyridine calcium antagonists, while exhibiting a diminished spectrum of adverse effects relative to ACE inhibitors and non-dihydropyridine calcium blockers, thus occupying a critical niche in essential therapeutic regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-haemorrhage rectum-Indapamide"}]}}
{"custom_id": "Methylphenidate-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-angina-Terazosin"}]}}
{"custom_id": "mitomycin C-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: mitomycin C\nDRUG 1 BACKGROUND INFORMATION: Mitomycin C is a mitomycin that is used as a  chemotherapeutic agent by virtue of its antitumour activity.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): mitomycin C-myelodysplasia-vincristine"}]}}
{"custom_id": "Diazepam-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-micturition urgency-Perindopril"}]}}
{"custom_id": "Cetirizine-Pyridostigmine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-Bleeding-Pyridostigmine"}]}}
{"custom_id": "Methylphenidate-Ziprasidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-cholecystitis-Ziprasidone"}]}}
{"custom_id": "Celecoxib-chlortalidone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: chlortalidone\nDRUG 2 BACKGROUND INFORMATION: Chlortalidone, a thiazide-like sulfonamide diuretic, is predominantly prescribed for antihypertensive therapy and states of edema associated with heart failure, hepatic cirrhosis, and nephrotic syndrome, as well as for managing nephrogenic diabetes insipidus and renal tubular acidosis. Its pharmacodynamic efficacy stems from modulating renal sodium and water excretion, thereby affecting volume and pressure homeostasis; the precise mechanistic pathways, however, remain partially elucidated. Its pharmacokinetic profile reveals oral bioavailability with an onset of diuresis within approximately three hours, sustaining therapeutic effects for up to 72 hours. Comparative studies suggest chlortalidone's superior cardiovascular outcome efficacy over hydrochlorothiazide in long-term stroke and myocardial infarction prophylaxis, despite a contentious spectrum of adverse effect profiles, including hypokalemia, hyponatremia, hyperglycemia, orthostatic hypotension, and reduced erectile function, alongside rarer occurrences of gout, hypomagnesemia, hypercalcemia, and hypersensitivity reactions. Pregnancy use, although possible, is approached with caution due to alternative preferred therapeutics. As part of the WHO's essential medicines list, chlortalidone remains a critical agent in hypertension management, widely available as a cost-effective generic, reflecting its substantial utilization in clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-apoplexy-chlortalidone"}]}}
{"custom_id": "Aciclovir-Ganciclovir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Ganciclovir\nDRUG 2 BACKGROUND INFORMATION: Ganciclovir, sold under the brand name Cytovene among others, is an antiviral medication used to treat cytomegalovirus (CMV) infections.\nGanciclovir was patented in 1980 and approved for medical use in 1988.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-right heart failure-Ganciclovir"}]}}
{"custom_id": "Ketoprofen-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-insomnia-Lamivudine"}]}}
{"custom_id": "Risedronic acid-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-erythema-Zolpidem"}]}}
{"custom_id": "Famotidine-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-elevated cholesterol-Pirbuterol"}]}}
{"custom_id": "Duloxetine-Acamprosate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: Acamprosate\nDRUG 2 BACKGROUND INFORMATION: Acamprosate, sold under the brand name Campral, is a medication which reduces cravings in alcoholism. It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals, as it only addresses withdrawal symptoms and not psychological dependence. It facilitates a reduction in alcohol consumption as well as full abstinence when used in combination with psychosocial support or other drugs that address the addictive behavior.\nSerious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side effect. It is unclear if use is safe during pregnancy.\nIt is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-nausea-Acamprosate"}]}}
{"custom_id": "Temazepam-Megestrol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Megestrol\nDRUG 2 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-cholecystitis-Megestrol"}]}}
{"custom_id": "Candesartan-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-gastric inflammation-Duloxetine"}]}}
{"custom_id": "Sildenafil-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Sildenafil\nDRUG 1 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Sildenafil-apoplexy-Zaleplon"}]}}
{"custom_id": "Risedronic acid-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-Sinus headache-Imatinib"}]}}
{"custom_id": "Furosemide-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-haemorrhage rectum-Telithromycin"}]}}
{"custom_id": "Citalopram-nevirapine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: nevirapine\nDRUG 2 BACKGROUND INFORMATION: Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.\nCommon side effects include rash, headache, nausea, feeling tired, and liver problems. The liver problems and skin rash may be severe and should be checked for during the first few months of treatment. It appears to be safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.\nNevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-loss of weight-nevirapine"}]}}
{"custom_id": "Bumetanide-Fenofibrate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Bumetanide\nDRUG 1 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG 2 NAME: Fenofibrate\nDRUG 2 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Bumetanide-hepatic neoplasia-Fenofibrate"}]}}
{"custom_id": "folinic acid-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: folinic acid\nDRUG 1 BACKGROUND INFORMATION: Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.\nSide effects may include trouble sleeping, allergic reactions, or fever. Use in pregnancy or breastfeeding is generally regarded as safe. When used for anemia it is recommended that pernicious anemia as a cause be ruled out first. Folinic acid is a form of folic acid that does not require activation by dihydrofolate reductase to be useful to the body.\nFolinic acid was first made in 1945. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): folinic acid-eruption-Thalidomide"}]}}
{"custom_id": "Diazepam-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-gastric inflammation-Ibuprofen"}]}}
{"custom_id": "Naproxen-Palonosetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Palonosetron\nDRUG 2 BACKGROUND INFORMATION: Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.\nPalonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than  other 5-HT3 antagonists. The oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. It is on the World Health Organization's List of Essential Medicines.\nThe oral combination netupitant/palonosetron is approved for both acute and delayed CINV.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Palonosetron"}]}}
{"custom_id": "Alprazolam-Formoterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Formoterol\nDRUG 2 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-loss of weight-Formoterol"}]}}
{"custom_id": "Fentanyl-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-dysarthria-Trimethoprim"}]}}
{"custom_id": "Citalopram-Midodrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Midodrine\nDRUG 2 BACKGROUND INFORMATION: Midodrine, sold under the brand names ProAmatine and Orvaten among others, is an antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence. It is taken by mouth.\nSide effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. Midodrine is a prodrug of its active metabolite desglymidodrine. This metabolite acts as a selective agonist of the \u03b11-adrenergic receptor. This in turn results in vasoconstriction and increased blood pressure.\nMidodrine was discovered by 1971 and was introduced for medical use in the United States in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-haematoma-Midodrine"}]}}
{"custom_id": "Duloxetine-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-loss of weight-solifenacin"}]}}
{"custom_id": "Rofecoxib-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-eruption-Imatinib"}]}}
{"custom_id": "Diazepam-Ketoprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Ketoprofen\nDRUG 2 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-cholecystitis-Ketoprofen"}]}}
{"custom_id": "Diazepam-Temozolomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Temozolomide\nDRUG 2 BACKGROUND INFORMATION: Temozolomide is a cytotoxic alkylating agent employed primarily in neuro-oncology for the management of high-grade gliomas, including glioblastoma multiforme and anaplastic astrocytoma, administered orally or intravenously. The therapeutic action involves DNA methylation at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis, particularly effective in the presence of MGMT promoter methylation, enhancing chemosensitivity. Adverse hematologic effects largely manifest as myelosuppression, including neutropenia, lymphopenia, and thrombocytopenia, alongside gastrointestinal disturbances such as emesis and anorexia, dermatological reactions typified by alopecia and rash, and neurological symptoms like convulsions and fatigue. Additionally, temozolomide's synergistic efficacy with PARP inhibitors, notably olaparib, extends its utility in salvage therapy for recalcitrant malignancies like relapsed small cell lung cancer, augmenting its strategic application in oncology pharmacotherapy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-drug toxicity NOS-Temozolomide"}]}}
{"custom_id": "Naproxen-Pyridostigmine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-erythema-Pyridostigmine"}]}}
{"custom_id": "Temozolomide-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temozolomide\nDRUG 1 BACKGROUND INFORMATION: Temozolomide is a cytotoxic alkylating agent employed primarily in neuro-oncology for the management of high-grade gliomas, including glioblastoma multiforme and anaplastic astrocytoma, administered orally or intravenously. The therapeutic action involves DNA methylation at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis, particularly effective in the presence of MGMT promoter methylation, enhancing chemosensitivity. Adverse hematologic effects largely manifest as myelosuppression, including neutropenia, lymphopenia, and thrombocytopenia, alongside gastrointestinal disturbances such as emesis and anorexia, dermatological reactions typified by alopecia and rash, and neurological symptoms like convulsions and fatigue. Additionally, temozolomide's synergistic efficacy with PARP inhibitors, notably olaparib, extends its utility in salvage therapy for recalcitrant malignancies like relapsed small cell lung cancer, augmenting its strategic application in oncology pharmacotherapy.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temozolomide-body temperature increased-Trimethoprim"}]}}
{"custom_id": "Oxaprozin-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Oxaprozin\nDRUG 1 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Oxaprozin-gastric inflammation-Sildenafil"}]}}
{"custom_id": "Citalopram-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-allergic dermatitis-Darunavir"}]}}
{"custom_id": "Famotidine-melphalan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: melphalan\nDRUG 2 BACKGROUND INFORMATION: Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.\nCommon side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.\nMelphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-cholecystitis-melphalan"}]}}
{"custom_id": "Rofecoxib-Balsalazide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Balsalazide\nDRUG 2 BACKGROUND INFORMATION: Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.\nIt is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. It is in the category of disease-modifying antirheumatic drugs (DMARDs) family of medications. It is unclear exactly how it works.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-atelectasis-Balsalazide"}]}}
{"custom_id": "Tramadol-Almotriptan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Almotriptan\nDRUG 2 BACKGROUND INFORMATION: Almotriptan  (trade name Axert and others) is a triptan medication discovered and developed by Almirall for the treatment of heavy migraine headache.\nIt was patented in 1992 and approved for medical use in 2000.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tramadol-loss of weight-Almotriptan"}]}}
{"custom_id": "Rofecoxib-Telmisartan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-cholecystitis-Telmisartan"}]}}
{"custom_id": "Triazolam-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Triazolam\nDRUG 1 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Triazolam-neumonia-Rosiglitazone"}]}}
{"custom_id": "Naproxen-Dapsone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Dapsone"}]}}
{"custom_id": "Metronidazole-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-drug toxicity NOS-Terazosin"}]}}
{"custom_id": "Diazepam-Moexipril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Moexipril\nDRUG 2 BACKGROUND INFORMATION: Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. \nIt works by inhibiting the conversion of angiotensin I to angiotensin II. \nIt was patented in 1980 and approved for medical use in 1995. Moexipril is available from Schwarz Pharma under the trade name Univasc.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-insulin dependent diabetes mellitus-Moexipril"}]}}
{"custom_id": "Methylphenidate-Megestrol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Megestrol\nDRUG 2 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-gastric inflammation-Megestrol"}]}}
{"custom_id": "Citalopram-Gemfibrozil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-metabolic encephalopathy-Gemfibrozil"}]}}
{"custom_id": "Lamotrigine-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-bulging-Oxaprozin"}]}}
{"custom_id": "Citalopram-Palonosetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Palonosetron\nDRUG 2 BACKGROUND INFORMATION: Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.\nPalonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than  other 5-HT3 antagonists. The oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. It is on the World Health Organization's List of Essential Medicines.\nThe oral combination netupitant/palonosetron is approved for both acute and delayed CINV.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-failure to thrive-Palonosetron"}]}}
{"custom_id": "Metronidazole-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-gastric inflammation-Zolpidem"}]}}
{"custom_id": "Tramadol-Telmisartan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tramadol-cholecystitis-Telmisartan"}]}}
{"custom_id": "Cetirizine-Dipyridamole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Dipyridamole\nDRUG 2 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-apoplexy-Dipyridamole"}]}}
{"custom_id": "Methylphenidate-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-Back Ache-Trazodone"}]}}
{"custom_id": "Duloxetine-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-narcolepsy-Darunavir"}]}}
{"custom_id": "Aciclovir-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-abdominal pain upper-Trimethoprim"}]}}
{"custom_id": "Ondansetron-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-cholecystitis-Salmeterol"}]}}
{"custom_id": "Fentanyl-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-back injury-Trazodone"}]}}
{"custom_id": "Metolazone-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metolazone-Adenopathy-Pamidronic acid"}]}}
{"custom_id": "Cetirizine-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-cholecystitis-Salmeterol"}]}}
{"custom_id": "Ticlopidine-Tirofiban-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ticlopidine\nDRUG 1 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG 2 NAME: Tirofiban\nDRUG 2 BACKGROUND INFORMATION: Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.\nIt is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ticlopidine-thrombocytopenia-Tirofiban"}]}}
{"custom_id": "Gabapentin-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-Back Ache-Telithromycin"}]}}
{"custom_id": "Alprazolam-Fluorouracil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Fluorouracil\nDRUG 2 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-haemorrhage rectum-Fluorouracil"}]}}
{"custom_id": "folinic acid-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: folinic acid\nDRUG 1 BACKGROUND INFORMATION: Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.\nSide effects may include trouble sleeping, allergic reactions, or fever. Use in pregnancy or breastfeeding is generally regarded as safe. When used for anemia it is recommended that pernicious anemia as a cause be ruled out first. Folinic acid is a form of folic acid that does not require activation by dihydrofolate reductase to be useful to the body.\nFolinic acid was first made in 1945. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): folinic acid-abnormal ECG-Pamidronic acid"}]}}
{"custom_id": "Fentanyl-Ketamine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ketamine\nDRUG 2 BACKGROUND INFORMATION: Ketamine, a phencyclidine derivative, serves as a non-competitive NMDA receptor antagonist, primarily utilized in clinical anesthesiology for induction and maintenance due to its unique ability to induce a state of dissociative anesthesia characterized by analgesia, sedation, and amnesia, while preserving autonomic reflexes, respiratory function, and cardiovascular stimulatory effects, such as increased cardiac output and moderate bronchodilation. Its pharmacokinetics allow lower, sub-anesthetic dosages to mitigate treatment-resistant depression and chronic pain, although the attenuation of therapeutic effects with time necessitates repeated administrations or adjunctive strategies. Despite its clinical utilities, ketamine's dissociative and hallucinogenic properties foster its illicit recreational use, often termed \"Special K,\" with prurience towards both nascent and profound psychotropic experiences, compounded by long-term hepatic and lower urinary tract toxicity risks in habitual users. The drug\u2019s presence spans both human and veterinary medicine, underscored by its inclusion on the WHO's List of Essential Medicines, reflecting its essential pharmacological versatility and accessibility as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-disseminated lupus erythematosus-Ketamine"}]}}
{"custom_id": "Risedronic acid-Telmisartan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-apoplexy-Telmisartan"}]}}
{"custom_id": "Amlodipine-Dapsone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-cholecystitis-Dapsone"}]}}
{"custom_id": "Famotidine-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Propofol"}]}}
{"custom_id": "alendronic acid-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Imatinib"}]}}
{"custom_id": "Citalopram-hydralazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: hydralazine\nDRUG 2 BACKGROUND INFORMATION: Hydralazine, a direct-acting vasodilator, primarily functions by eliciting arteriolar smooth muscle relaxation leading to decreased peripheral resistance and afterload, effectively lowering systemic blood pressure, particularly useful in hypertensive emergencies and heart failure. Its mechanism involves interference with intracellular calcium dynamics and modulation of nitric oxide signaling, highly favored in conjunction with isosorbide dinitrate for African American patients presenting with heart failure. Its pharmacokinetics reveal an onset of action approximately 15 minutes post-administration, with bioavailability subjected to first-pass metabolism, and a duration of effect extending up to six hours. Contraindications include coronary artery disease and mitral valvulopathy secondary to rheumatic heart disease, and caution is warranted in renal impairment necessitating dosage adjustments. Adverse effects, such as reflex tachycardia and cephalalgia, stem from compensatory sympathetic activation, thus contraindicating use in tachycardiac or CAD patients. Its inclusion on the WHO's List of Essential Medicines underscores its clinical significance, albeit it is low-cost and widely utilized, reflecting its extensive prescription volume.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-muscle disorder-hydralazine"}]}}
{"custom_id": "Aciclovir-Dipyridamole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Dipyridamole\nDRUG 2 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-eruption-Dipyridamole"}]}}
{"custom_id": "Rosiglitazone-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rosiglitazone\nDRUG 1 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rosiglitazone-Adenopathy-Bimatoprost"}]}}
{"custom_id": "Metronidazole-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-metabolic encephalopathy-Thalidomide"}]}}
{"custom_id": "acetazolamide-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-allergic dermatitis-Propofol"}]}}
{"custom_id": "Metoprolol-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metoprolol\nDRUG 1 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 2 NAME: Fulvestrant\nDRUG 2 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metoprolol-abdominal pain upper-Fulvestrant"}]}}
{"custom_id": "Celecoxib-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Fulvestrant\nDRUG 2 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Sinus headache-Fulvestrant"}]}}
{"custom_id": "Aciclovir-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-cholecystitis-Ibuprofen"}]}}
{"custom_id": "Metronidazole-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-Acute Respiratory Distress Syndrome-vincristine"}]}}
{"custom_id": "Megestrol-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Megestrol\nDRUG 1 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Megestrol-ADVERSE DRUG EFFECT-Sorafenib"}]}}
{"custom_id": "indometacin-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-elevated erythrocyte sedimentation rate-Pamidronic acid"}]}}
{"custom_id": "Bumetanide-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Bumetanide\nDRUG 1 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Bumetanide-neumonia-vincristine"}]}}
{"custom_id": "Doxazosin-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-atelectasis-Pamidronic acid"}]}}
{"custom_id": "Methylphenidate-Erlotinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Erlotinib\nDRUG 2 BACKGROUND INFORMATION: Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.\nCommon side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).\nErlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-Bacteraemia-Erlotinib"}]}}
{"custom_id": "Paracetamol-Tirofiban-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Paracetamol\nDRUG 1 BACKGROUND INFORMATION: Paracetamol, or acetaminophen, functions as a para-aminophenol derivative providing analgesic and antipyretic effects predominantly by inhibiting COX enzymes within the central nervous system; however, its peripheral anti-inflammatory impact is minimal compared to nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. It is therapeutically advantageous for alleviating mild to moderate pain in conditions such as acute mild migraine and episodic tension headaches, though the analgesic efficacy is modest in osteoarthritic and low back pain contexts, with negligible evidence supporting its utility in cancer and neuropathic pain management. Paracetamol at standard dosing mitigates fever to a limited extent; however, it is suboptimal compared to ibuprofen, particularly in febrile states of viral etiology, rendering its role in antipyresis debatable. Despite its generally safe profile when administered short-term and adherence to a maximum recommended dosage of three to four grams daily, paracetamol harbors hepatotoxic potential when overdosed, being a preeminent cause of drug-induced acute hepatic failure in Western populations. Its metabolic pathway in the liver, involving cytochrome P450 enzymes and subsequent depletion of glutathione reserves, underscores the mechanism of hepatotoxicity. Chronic use may elicit gastrointestinal bleeding and hepatic dysfunction, whereas its utilization might be beneficial for patients contraindicated for NSAID therapy. Clinically, combination therapies, such as with ibuprofen, exhibit increased analgesic efficacy, while the triple combination of aspirin, paracetamol, and caffeine remains a preferred first-line intervention for mild pain syndromes. Paracetamol\u2019s clinical application persists widely, inscribed on the World Health Organization's List of Essential Medicines, and forecasts substantial prescription numbers globally.\n\nDRUG 2 NAME: Tirofiban\nDRUG 2 BACKGROUND INFORMATION: Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.\nIt is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Paracetamol-thrombocytopenia-Tirofiban"}]}}
{"custom_id": "Celecoxib-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Adenopathy-Imatinib"}]}}
{"custom_id": "Ranitidine-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-gastric inflammation-Zolpidem"}]}}
{"custom_id": "Dipyridamole-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dipyridamole\nDRUG 1 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dipyridamole-weight gain-Sildenafil"}]}}
{"custom_id": "Ketoprofen-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-nasopharyngitis-Pamidronic acid"}]}}
{"custom_id": "Methylphenidate-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-agitated-Imatinib"}]}}
{"custom_id": "Desloratadine-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Desloratadine\nDRUG 1 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Desloratadine-acute pancreatitis-Darunavir"}]}}
{"custom_id": "Labetalol-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Labetalol\nDRUG 1 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol"}]}}
{"custom_id": "Bumetanide-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Bumetanide\nDRUG 1 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Bumetanide-weight gain-Torasemide"}]}}
{"custom_id": "Cimetidine-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-erythema-Pamidronic acid"}]}}
{"custom_id": "indometacin-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-arterial pressure NOS increased-Torasemide"}]}}
{"custom_id": "Lamotrigine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-loss of weight-Torasemide"}]}}
{"custom_id": "oxybutynin-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: oxybutynin\nDRUG 1 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): oxybutynin-apoplexy-Pirbuterol"}]}}
{"custom_id": "Metoprolol-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metoprolol\nDRUG 1 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metoprolol-Dyspnea exertional-Bimatoprost"}]}}
{"custom_id": "Naproxen-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-oxybutynin"}]}}
{"custom_id": "Cimetidine-Labetalol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-back injury-Labetalol"}]}}
{"custom_id": "Cimetidine-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-angiitis-hydroxychloroquine"}]}}
{"custom_id": "Gabapentin-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-erythema-hydroxychloroquine"}]}}
{"custom_id": "Doxazosin-Fluorouracil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Fluorouracil\nDRUG 2 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-loss of weight-Fluorouracil"}]}}
{"custom_id": "Metolazone-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metolazone-drug toxicity NOS-Sildenafil"}]}}
{"custom_id": "Celecoxib-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-erythema-Zaleplon"}]}}
{"custom_id": "acetazolamide-Citalopram-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Citalopram"}]}}
{"custom_id": "Gabapentin-Ketorolac-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Ketorolac\nDRUG 2 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-adenomyosis-Ketorolac"}]}}
{"custom_id": "Sildenafil-Acamprosate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Sildenafil\nDRUG 1 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 2 NAME: Acamprosate\nDRUG 2 BACKGROUND INFORMATION: Acamprosate, sold under the brand name Campral, is a medication which reduces cravings in alcoholism. It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals, as it only addresses withdrawal symptoms and not psychological dependence. It facilitates a reduction in alcohol consumption as well as full abstinence when used in combination with psychosocial support or other drugs that address the addictive behavior.\nSerious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side effect. It is unclear if use is safe during pregnancy.\nIt is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Sildenafil-loss of weight-Acamprosate"}]}}
{"custom_id": "Naproxen-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-edema-Zaleplon"}]}}
{"custom_id": "Carvedilol-Tirofiban-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Tirofiban\nDRUG 2 BACKGROUND INFORMATION: Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.\nIt is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-thrombocytopenia-Tirofiban"}]}}
{"custom_id": "Cetirizine-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-Thrombophlebitis-vincristine"}]}}
{"custom_id": "Lamotrigine-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-apoplexy-Zaleplon"}]}}
{"custom_id": "Celecoxib-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-gastric inflammation-Ibuprofen"}]}}
{"custom_id": "Ketorolac-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-gastric inflammation-Oxaprozin"}]}}
{"custom_id": "phenytoin-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: phenytoin\nDRUG 1 BACKGROUND INFORMATION: Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): phenytoin-abnormal EEG-Propofol"}]}}
{"custom_id": "Modafinil-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Modafinil\nDRUG 1 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Modafinil-nocturia-Bimatoprost"}]}}
{"custom_id": "Fentanyl-Ketorolac-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ketorolac\nDRUG 2 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Ketorolac"}]}}
{"custom_id": "Fentanyl-Aminophylline-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Aminophylline\nDRUG 2 BACKGROUND INFORMATION: Aminophylline is a compound of the bronchodilator theophylline with ethylenediamine in 2:1 ratio. The ethylenediamine improves solubility, and the aminophylline is usually found as a dihydrate.\nAminophylline is less potent and shorter-acting than theophylline. Its most common use is in the treatment of airway obstruction from asthma or COPD. Aminophylline is a nonselective adenosine receptor antagonist and phosphodiesterase inhibitor.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-thrombocytopenia-Aminophylline"}]}}
{"custom_id": "Ibuprofen-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-dysarthria-Propofol"}]}}
{"custom_id": "Fentanyl-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-gastric inflammation-Dexpramipexole"}]}}
{"custom_id": "Amlodipine-Exemestane-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Exemestane\nDRUG 2 BACKGROUND INFORMATION: Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-Pain-Exemestane"}]}}
{"custom_id": "Alprazolam-Ciclopirox-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Ciclopirox\nDRUG 2 BACKGROUND INFORMATION: Ciclopirox is a medication used for the treatment of moderate onychomycosis of fingernails and toenails, and for the treatment of seborrheic dermatitis.\nIn 2022, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-arterial pressure NOS decreased-Ciclopirox"}]}}
{"custom_id": "Desloratadine-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Desloratadine\nDRUG 1 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Desloratadine-Sinus headache-Telithromycin"}]}}
{"custom_id": "Risedronic acid-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-failure to thrive-Trazodone"}]}}
{"custom_id": "Naproxen-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Pirbuterol"}]}}
{"custom_id": "Duloxetine-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Duloxetine-gastric inflammation-Desloratadine"}]}}
{"custom_id": "Alfuzosin-Benazepril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alfuzosin\nDRUG 1 BACKGROUND INFORMATION: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the \u03b11 blocker class. It is used to treat benign prostatic hyperplasia (BPH).\nAs an antagonist of the \u03b11-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier. \nAlfuzosin was patented in 1978 and approved for medical use in 1988. It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alfuzosin-Decreased Libido-Benazepril"}]}}
{"custom_id": "Amlodipine-Ganciclovir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Ganciclovir\nDRUG 2 BACKGROUND INFORMATION: Ganciclovir, sold under the brand name Cytovene among others, is an antiviral medication used to treat cytomegalovirus (CMV) infections.\nGanciclovir was patented in 1980 and approved for medical use in 1988.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-angiitis-Ganciclovir"}]}}
{"custom_id": "Chloroquine-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Chloroquine\nDRUG 1 BACKGROUND INFORMATION: Chloroquine, a 4-aminoquinoline class antiparasitic agent, primarily exerts its antimalarial effects by disrupting Plasmodium spp. asexual intraerythrocytic stages through the accumulation of toxic haem within the parasite's acidic food vacuoles, thus hindering haemozoin biocrystallization and ultimately leading to plasmodicidal activity. Resistance phenomena necessitate adjunctive or alternative therapeutics, particularly among certain Plasmodium falciparum isolates. Beyond malaria, chloroquine demonstrates efficacy in extra-intestinal amoebiasis and provides therapeutic benefit in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus, though the mechanistic pathways in these diseases remain elusive. Orally administered, chloroquine's adverse profile includes neuromuscular, dermatological, and gastrointestinal disturbances, with severe toxicities encompassing retinopathy, cardiomyopathy, and hematologic dyscrasias. Despite exploratory investigations during the COVID-19 pandemic, the NIH advises against its use due to inefficacious outcomes in controlled trials. Chloroquine's inclusion in the World Health Organization's compendium of essential medicines underscores its indispensable role in therapeutics, and its established genetic availability ensures widespread access.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Chloroquine-loss of weight-hydroxychloroquine"}]}}
{"custom_id": "acetazolamide-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Hypoventilation-Dexpramipexole"}]}}
{"custom_id": "Citalopram-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-oxybutynin"}]}}
{"custom_id": "Desloratadine-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Desloratadine\nDRUG 1 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Desloratadine-bursitis-solifenacin"}]}}
{"custom_id": "Ofloxacin-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ofloxacin\nDRUG 1 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-cholecystitis-Torasemide"}]}}
{"custom_id": "alendronic acid-Dipyridamole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Dipyridamole\nDRUG 2 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-erythema-Dipyridamole"}]}}
{"custom_id": "Temazepam-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-gastric inflammation-Trazodone"}]}}
{"custom_id": "Furosemide-gadoversetamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: gadoversetamide\nDRUG 2 BACKGROUND INFORMATION: Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver. It is marketed under the trade name OptiMARK.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-Scleroderma-gadoversetamide"}]}}
{"custom_id": "Ketoprofen-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-thrombocytopenia-Telithromycin"}]}}
{"custom_id": "Candesartan-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-elevated erythrocyte sedimentation rate-Sildenafil"}]}}
{"custom_id": "Isoniazid-Emtricitabine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Isoniazid\nDRUG 1 BACKGROUND INFORMATION: Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.\n\nDRUG 2 NAME: Emtricitabine\nDRUG 2 BACKGROUND INFORMATION: Emtricitabine (FTC; 2',3'-dideoxy-5-fluoro-3'-thiacytidine) operates as a potent nucleoside reverse-transcriptase inhibitor (NRTI) indicated for both prophylaxis and active management of HIV infection across diverse age cohorts. This molecule is integral to the composition of the Quad pill, specifically Stribild and Genvoya, and is prominently featured in fixed-dose co-formulations with tenofovir disoproxil as Truvada and with tenofovir alafenamide as Descovy, underscoring its critical role in multi-drug regimens. Emtricitabine's strategic inclusion in these combinations has earned it placement on the WHO's List of Essential Medicines, reflecting its indispensable utility in comprehensive antiretroviral therapy. Notably, the FDA-approved fixed-dose triple combination incorporating emtricitabine, tenofovir, and efavirenz, commercially available as Atripla, exemplifies its integration into optimized antiretroviral protocols aimed at maximizing therapeutic efficacy and medication adherence.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Isoniazid-enlarged liver-Emtricitabine"}]}}
{"custom_id": "Celecoxib-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Adenopathy-Oxaprozin"}]}}
{"custom_id": "Ibuprofen-Repaglinide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Repaglinide\nDRUG 2 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-renal abscess-Repaglinide"}]}}
{"custom_id": "Ibuprofen-Adapalene-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Adapalene\nDRUG 2 BACKGROUND INFORMATION: Adapalene, sold under the brand name Differin among others, is a third-generation topical retinoid primarily used in the treatment of mild-moderate acne, and is also used off-label to treat keratosis pilaris as well as other skin conditions. Studies have found adapalene is as effective as other retinoids, while causing less irritation. It also has several advantages over other retinoids. The adapalene molecule is more stable compared to tretinoin and tazarotene, which leads to less concern for photodegradation. It is also chemically more stable compared to the other two retinoids, allowing it to be used in combination with benzoyl peroxide. Due to its effects on keratinocyte proliferation and differentiation, adapalene is superior to tretinoin for the treatment of comedonal acne and is often used as a first-line agent. The Swiss company Galderma developed adapalene.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-periodontitis-Adapalene"}]}}
{"custom_id": "Rofecoxib-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-erythema-Thalidomide"}]}}
{"custom_id": "Fentanyl-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ticlopidine\nDRUG 2 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-bulging-Ticlopidine"}]}}
{"custom_id": "Ibuprofen-Midodrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Midodrine\nDRUG 2 BACKGROUND INFORMATION: Midodrine, sold under the brand names ProAmatine and Orvaten among others, is an antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence. It is taken by mouth.\nSide effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. Midodrine is a prodrug of its active metabolite desglymidodrine. This metabolite acts as a selective agonist of the \u03b11-adrenergic receptor. This in turn results in vasoconstriction and increased blood pressure.\nMidodrine was discovered by 1971 and was introduced for medical use in the United States in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-dry skin-Midodrine"}]}}
{"custom_id": "Carvedilol-Ranolazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Ranolazine\nDRUG 2 BACKGROUND INFORMATION: Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.\nCommon side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.\nRanolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-Infection Upper Respiratory-Ranolazine"}]}}
{"custom_id": "Fentanyl-Adapalene-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Adapalene\nDRUG 2 BACKGROUND INFORMATION: Adapalene, sold under the brand name Differin among others, is a third-generation topical retinoid primarily used in the treatment of mild-moderate acne, and is also used off-label to treat keratosis pilaris as well as other skin conditions. Studies have found adapalene is as effective as other retinoids, while causing less irritation. It also has several advantages over other retinoids. The adapalene molecule is more stable compared to tretinoin and tazarotene, which leads to less concern for photodegradation. It is also chemically more stable compared to the other two retinoids, allowing it to be used in combination with benzoyl peroxide. Due to its effects on keratinocyte proliferation and differentiation, adapalene is superior to tretinoin for the treatment of comedonal acne and is often used as a first-line agent. The Swiss company Galderma developed adapalene.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-periodontitis-Adapalene"}]}}
{"custom_id": "alendronic acid-Pyridostigmine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-gastric inflammation-Pyridostigmine"}]}}
{"custom_id": "Ciclopirox-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ciclopirox\nDRUG 1 BACKGROUND INFORMATION: Ciclopirox is a medication used for the treatment of moderate onychomycosis of fingernails and toenails, and for the treatment of seborrheic dermatitis.\nIn 2022, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ciclopirox-Adenopathy-hydroxychloroquine"}]}}
{"custom_id": "Ofloxacin-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ofloxacin\nDRUG 1 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 2 NAME: thiotepa\nDRUG 2 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-enlarged spleen-thiotepa"}]}}
{"custom_id": "Alprazolam-Doxazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-myelodysplasia-Doxazosin"}]}}
{"custom_id": "Amlodipine-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-increased white blood cell count-vincristine"}]}}
{"custom_id": "Cimetidine-Palonosetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Palonosetron\nDRUG 2 BACKGROUND INFORMATION: Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.\nPalonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than  other 5-HT3 antagonists. The oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. It is on the World Health Organization's List of Essential Medicines.\nThe oral combination netupitant/palonosetron is approved for both acute and delayed CINV.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-erythema multiforme-Palonosetron"}]}}
{"custom_id": "Diazepam-Fenofibrate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Fenofibrate\nDRUG 2 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-metabolic encephalopathy-Fenofibrate"}]}}
{"custom_id": "Naproxen-Ketoprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Ketoprofen\nDRUG 2 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Ketoprofen"}]}}
{"custom_id": "Lamotrigine-Pilocarpine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Pilocarpine\nDRUG 2 BACKGROUND INFORMATION: Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-agitated-Pilocarpine"}]}}
{"custom_id": "Citalopram-Ranolazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Ranolazine\nDRUG 2 BACKGROUND INFORMATION: Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.\nCommon side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.\nRanolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-bursitis-Ranolazine"}]}}
{"custom_id": "Metronidazole-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-narcolepsy-Duloxetine"}]}}
{"custom_id": "Sibutramine-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Sibutramine\nDRUG 1 BACKGROUND INFORMATION: Sibutramine, a pharmacological intervention formerly indicated for obesity management, operates through its mechanism as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), akin to certain antidepressant modalities, modulating monoamine neurotransmitter pathways to exert anorectic effects. Despite its initial widespread utilization, it was contraindicated due to a correlation with augmented cardiovascular morbidity and cerebrovascular incidents, prompting market withdrawal across multiple jurisdictions including Australia, the European Union, and the United States by 2010. Developed by Boots Pharmaceuticals and subsequently commercialized by Abbott Laboratories under trade names such as Meridia and Reductil, sibutramine was a Schedule IV controlled entity in the United States before its discontinuation. However, the compound persists in unregulated domains, as evidenced by FDA findings of its presence in numerous purported \"natural\" or \"herbal\" supplements as recently as 2018, underscoring challenges in illicit pharmacovigilance.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Sibutramine-loss of weight-Zolpidem"}]}}
{"custom_id": "Tramadol-Exemestane-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Exemestane\nDRUG 2 BACKGROUND INFORMATION: Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tramadol-neumonia-Exemestane"}]}}
{"custom_id": "Diazepam-Doxazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-right heart failure-Doxazosin"}]}}
{"custom_id": "acetazolamide-Lidocaine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-exophthalmos-Lidocaine"}]}}
{"custom_id": "Fluorouracil-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fluorouracil\nDRUG 1 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fluorouracil-Bleeding-vincristine"}]}}
{"custom_id": "Fentanyl-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: desvenlafaxine\nDRUG 2 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-nervous tension-desvenlafaxine"}]}}
{"custom_id": "Risedronic acid-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-gastric inflammation-Perindopril"}]}}
{"custom_id": "Candesartan-Amiloride-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Amiloride\nDRUG 2 BACKGROUND INFORMATION: Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-Back Ache-Amiloride"}]}}
{"custom_id": "Cetirizine-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-erythema-Sildenafil"}]}}
{"custom_id": "Benazepril-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Benazepril\nDRUG 1 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Benazepril-apoplexy-Terazosin"}]}}
{"custom_id": "nevirapine-Ofloxacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: nevirapine\nDRUG 1 BACKGROUND INFORMATION: Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.\nCommon side effects include rash, headache, nausea, feeling tired, and liver problems. The liver problems and skin rash may be severe and should be checked for during the first few months of treatment. It appears to be safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.\nNevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG 2 NAME: Ofloxacin\nDRUG 2 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): nevirapine-anogenital warts-Ofloxacin"}]}}
{"custom_id": "Gabapentin-Thalidomide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Thalidomide\nDRUG 2 BACKGROUND INFORMATION: Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-cholecystitis-Thalidomide"}]}}
{"custom_id": "Alfuzosin-Famotidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alfuzosin\nDRUG 1 BACKGROUND INFORMATION: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the \u03b11 blocker class. It is used to treat benign prostatic hyperplasia (BPH).\nAs an antagonist of the \u03b11-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier. \nAlfuzosin was patented in 1978 and approved for medical use in 1988. It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alfuzosin-thrombocytopenia-Famotidine"}]}}
{"custom_id": "Famotidine-Repaglinide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Repaglinide\nDRUG 2 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-erythema-Repaglinide"}]}}
{"custom_id": "Temazepam-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-gastric inflammation-Zolpidem"}]}}
{"custom_id": "Alprazolam-Benazepril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Benazepril"}]}}
{"custom_id": "phenytoin-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: phenytoin\nDRUG 1 BACKGROUND INFORMATION: Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.\n\nDRUG 2 NAME: Fosphenytoin\nDRUG 2 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): phenytoin-Drug hypersensitivity-Fosphenytoin"}]}}
{"custom_id": "Furosemide-hydralazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: hydralazine\nDRUG 2 BACKGROUND INFORMATION: Hydralazine, a direct-acting vasodilator, primarily functions by eliciting arteriolar smooth muscle relaxation leading to decreased peripheral resistance and afterload, effectively lowering systemic blood pressure, particularly useful in hypertensive emergencies and heart failure. Its mechanism involves interference with intracellular calcium dynamics and modulation of nitric oxide signaling, highly favored in conjunction with isosorbide dinitrate for African American patients presenting with heart failure. Its pharmacokinetics reveal an onset of action approximately 15 minutes post-administration, with bioavailability subjected to first-pass metabolism, and a duration of effect extending up to six hours. Contraindications include coronary artery disease and mitral valvulopathy secondary to rheumatic heart disease, and caution is warranted in renal impairment necessitating dosage adjustments. Adverse effects, such as reflex tachycardia and cephalalgia, stem from compensatory sympathetic activation, thus contraindicating use in tachycardiac or CAD patients. Its inclusion on the WHO's List of Essential Medicines underscores its clinical significance, albeit it is low-cost and widely utilized, reflecting its extensive prescription volume.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-bundle branch block right-hydralazine"}]}}
{"custom_id": "Famotidine-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-gastric inflammation-Sildenafil"}]}}
{"custom_id": "Amlodipine-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-erythema-Pamidronic acid"}]}}
{"custom_id": "Famotidine-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Fulvestrant\nDRUG 2 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-loss of weight-Fulvestrant"}]}}
{"custom_id": "Risedronic acid-mercaptopurine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: mercaptopurine\nDRUG 2 BACKGROUND INFORMATION: Mercaptopurine, a thiopurine analogue and antimetabolite, exerts its pharmacological action by interfering with purine nucleotide synthesis, thereby inhibiting the proliferation of rapidly dividing cells such as malignant and immune cells. Its primary clinical applications include the management of hematological malignancies like acute lymphocytic leukemia (ALL) and acute promyelocytic leukemia (APL), as well as the modulation of aberrant immune responses in conditions such as Crohn's disease and ulcerative colitis. Mercaptopurine is administered orally and often in conjunction with methotrexate for synergistic effects in ALL. Its pharmacokinetics is significantly influenced by polymorphisms in thiopurine S-methyltransferase (TPMT), with TPMT deficiency resulting in elevated risk of myelosuppression and other toxicities. Hepatotoxicity, gastrointestinal disturbances, and anorexia are amongst its prevalent adverse effects, while more severe sequelae include heightened oncogenic potential and pancreatitis. Its teratogenic potential contraindicates use in pregnancy. As a cornerstone of chemotherapeutic regimens, mercaptopurine is recognized on WHO's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-Pain-mercaptopurine"}]}}
{"custom_id": "Dofetilide-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dofetilide\nDRUG 1 BACKGROUND INFORMATION: Dofetilide is a class III antiarrhythmic agent. It is marketed under the trade name Tikosyn by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 \u03bcg of dofetilide. It is not available in Europe or Australia.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dofetilide-phlebothrombosis-Bimatoprost"}]}}
{"custom_id": "Ziprasidone-Acamprosate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ziprasidone\nDRUG 1 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 2 NAME: Acamprosate\nDRUG 2 BACKGROUND INFORMATION: Acamprosate, sold under the brand name Campral, is a medication which reduces cravings in alcoholism. It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals, as it only addresses withdrawal symptoms and not psychological dependence. It facilitates a reduction in alcohol consumption as well as full abstinence when used in combination with psychosocial support or other drugs that address the addictive behavior.\nSerious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side effect. It is unclear if use is safe during pregnancy.\nIt is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-Arrhythmia-Acamprosate"}]}}
{"custom_id": "Capecitabine-Erlotinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Capecitabine\nDRUG 1 BACKGROUND INFORMATION: Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.\nCommon side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.\nCapecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Erlotinib\nDRUG 2 BACKGROUND INFORMATION: Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.\nCommon side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).\nErlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Capecitabine-apoplexy-Erlotinib"}]}}
{"custom_id": "indometacin-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-erythema-Terazosin"}]}}
{"custom_id": "Fenofibrate-Modafinil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fenofibrate\nDRUG 1 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG 2 NAME: Modafinil\nDRUG 2 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fenofibrate-gastric inflammation-Modafinil"}]}}
{"custom_id": "Cetirizine-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cetirizine-cholecystitis-hydroxychloroquine"}]}}
{"custom_id": "Temazepam-mitomycin C-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: mitomycin C\nDRUG 2 BACKGROUND INFORMATION: Mitomycin C is a mitomycin that is used as a  chemotherapeutic agent by virtue of its antitumour activity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-gastric inflammation-mitomycin C"}]}}
{"custom_id": "Tramadol-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tramadol-dysarthria-Trimethoprim"}]}}
{"custom_id": "Gabapentin-Moexipril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Moexipril\nDRUG 2 BACKGROUND INFORMATION: Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. \nIt works by inhibiting the conversion of angiotensin I to angiotensin II. \nIt was patented in 1980 and approved for medical use in 1995. Moexipril is available from Schwarz Pharma under the trade name Univasc.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-hepatic neoplasia-Moexipril"}]}}
{"custom_id": "Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamivudine\nDRUG 1 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol"}]}}
{"custom_id": "Methylphenidate-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-weight gain-Pirbuterol"}]}}
{"custom_id": "Alfuzosin-Gemfibrozil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alfuzosin\nDRUG 1 BACKGROUND INFORMATION: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the \u03b11 blocker class. It is used to treat benign prostatic hyperplasia (BPH).\nAs an antagonist of the \u03b11-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier. \nAlfuzosin was patented in 1978 and approved for medical use in 1988. It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alfuzosin-enlarged spleen-Gemfibrozil"}]}}
{"custom_id": "Candesartan-Cinacalcet-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Cinacalcet\nDRUG 2 BACKGROUND INFORMATION: Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.\nThe most common side effects include nausea and vomiting.\nCinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-thrombocytopenia-Cinacalcet"}]}}
{"custom_id": "Naproxen-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-hydroxychloroquine"}]}}
{"custom_id": "Citalopram-Riluzole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Riluzole\nDRUG 2 BACKGROUND INFORMATION: Riluzole is a medication used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months. Riluzole is available in tablet and liquid form.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-deglutition disorder-Riluzole"}]}}
{"custom_id": "folinic acid-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: folinic acid\nDRUG 1 BACKGROUND INFORMATION: Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.\nSide effects may include trouble sleeping, allergic reactions, or fever. Use in pregnancy or breastfeeding is generally regarded as safe. When used for anemia it is recommended that pernicious anemia as a cause be ruled out first. Folinic acid is a form of folic acid that does not require activation by dihydrofolate reductase to be useful to the body.\nFolinic acid was first made in 1945. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): folinic acid-thrombocytopenia-Perindopril"}]}}
{"custom_id": "Famotidine-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-hydroxychloroquine"}]}}
{"custom_id": "Ibuprofen-Modafinil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Modafinil\nDRUG 2 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-Adenopathy-Modafinil"}]}}
{"custom_id": "Fentanyl-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-cholecystitis-Metolazone"}]}}
{"custom_id": "Lamotrigine-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-haemorrhage rectum-Sildenafil"}]}}
{"custom_id": "Citalopram-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Propofol\nDRUG 2 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-cataract-Propofol"}]}}
{"custom_id": "Diazepam-Gemfibrozil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-cholecystitis-Gemfibrozil"}]}}
{"custom_id": "Naproxen-Capecitabine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Capecitabine\nDRUG 2 BACKGROUND INFORMATION: Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.\nCommon side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.\nCapecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Capecitabine"}]}}
{"custom_id": "Gabapentin-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-gastric inflammation-Sildenafil"}]}}
{"custom_id": "alendronic acid-Moexipril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Moexipril\nDRUG 2 BACKGROUND INFORMATION: Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. \nIt works by inhibiting the conversion of angiotensin I to angiotensin II. \nIt was patented in 1980 and approved for medical use in 1995. Moexipril is available from Schwarz Pharma under the trade name Univasc.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-gastric inflammation-Moexipril"}]}}
{"custom_id": "Risedronic acid-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-Adenopathy-Terazosin"}]}}
{"custom_id": "Temazepam-Trimipramine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Trimipramine\nDRUG 2 BACKGROUND INFORMATION: Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or \"second-generation\" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-constipated-Trimipramine"}]}}
{"custom_id": "Ofloxacin-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ofloxacin\nDRUG 1 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-eruption-Darunavir"}]}}
{"custom_id": "Ketorolac-Ondansetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-Adenopathy-Ondansetron"}]}}
{"custom_id": "Amlodipine-Isoniazid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Isoniazid\nDRUG 2 BACKGROUND INFORMATION: Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-angiitis-Isoniazid"}]}}
{"custom_id": "Furosemide-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Fulvestrant\nDRUG 2 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-gastric inflammation-Fulvestrant"}]}}
{"custom_id": "Diazepam-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-cholecystitis-Desloratadine"}]}}
{"custom_id": "Metoprolol-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metoprolol\nDRUG 1 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metoprolol-erythema-Pirbuterol"}]}}
{"custom_id": "Risedronic acid-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-weight gain-vincristine"}]}}
{"custom_id": "Brimonidine-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Brimonidine\nDRUG 1 BACKGROUND INFORMATION: Brimonidine is an \u03b12-adrenergic agonist exhibiting therapeutic efficacy in attenuating open-angle glaucoma and ocular hypertension via modulation of intraocular pressure through dual mechanisms: decreased aqueous humor synthesis and enhanced uveoscleral outflow. Additionally, its vasoconstrictive action on cutaneous vasculature imparts symptomatic relief in erythema associated with rosacea when administered topically. The pharmacological profile is complemented by its inclusion in a fixed-dose compound with timolol maleate, enhancing antihypertensive efficacy. Ocular administration predisposes patients to localized side effects such as conjunctival hyperemia, pruritus, and xerostomia, whereas dermal application manifests as erythema, discomfort, and potential cephalgia. While systemic absorption is minimal, hypersensitivity reactions and hypotensive episodes warrant clinical vigilance. Brimonidine's safety profile in gravid populations is reassuring, and its generically available formulations have solidified its position as a mainstay in ophthalmic and dermatologic therapeutics, underscored by a substantial prescription volume.\n\nDRUG 2 NAME: hydroxychloroquine\nDRUG 2 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Brimonidine-loss of weight-hydroxychloroquine"}]}}
{"custom_id": "Amlodipine-Erlotinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Erlotinib\nDRUG 2 BACKGROUND INFORMATION: Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.\nCommon side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).\nErlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-subarachnoid haemorrhage-Erlotinib"}]}}
{"custom_id": "Naproxen-Norfloxacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Norfloxacin\nDRUG 2 BACKGROUND INFORMATION: Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.\nNorfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.\nIt was patented in 1977 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Atherosclerosis-Norfloxacin"}]}}
{"custom_id": "Candesartan-Ofloxacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Ofloxacin\nDRUG 2 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-gastric inflammation-Ofloxacin"}]}}
{"custom_id": "Ondansetron-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-cholecystitis-Telithromycin"}]}}
{"custom_id": "Carvedilol-melphalan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: melphalan\nDRUG 2 BACKGROUND INFORMATION: Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.\nCommon side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.\nMelphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-thrombocytopenia-melphalan"}]}}
{"custom_id": "alendronic acid-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-erythema-Perindopril"}]}}
{"custom_id": "Paracetamol-Disopyramide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Paracetamol\nDRUG 1 BACKGROUND INFORMATION: Paracetamol, or acetaminophen, functions as a para-aminophenol derivative providing analgesic and antipyretic effects predominantly by inhibiting COX enzymes within the central nervous system; however, its peripheral anti-inflammatory impact is minimal compared to nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. It is therapeutically advantageous for alleviating mild to moderate pain in conditions such as acute mild migraine and episodic tension headaches, though the analgesic efficacy is modest in osteoarthritic and low back pain contexts, with negligible evidence supporting its utility in cancer and neuropathic pain management. Paracetamol at standard dosing mitigates fever to a limited extent; however, it is suboptimal compared to ibuprofen, particularly in febrile states of viral etiology, rendering its role in antipyresis debatable. Despite its generally safe profile when administered short-term and adherence to a maximum recommended dosage of three to four grams daily, paracetamol harbors hepatotoxic potential when overdosed, being a preeminent cause of drug-induced acute hepatic failure in Western populations. Its metabolic pathway in the liver, involving cytochrome P450 enzymes and subsequent depletion of glutathione reserves, underscores the mechanism of hepatotoxicity. Chronic use may elicit gastrointestinal bleeding and hepatic dysfunction, whereas its utilization might be beneficial for patients contraindicated for NSAID therapy. Clinically, combination therapies, such as with ibuprofen, exhibit increased analgesic efficacy, while the triple combination of aspirin, paracetamol, and caffeine remains a preferred first-line intervention for mild pain syndromes. Paracetamol\u2019s clinical application persists widely, inscribed on the World Health Organization's List of Essential Medicines, and forecasts substantial prescription numbers globally.\n\nDRUG 2 NAME: Disopyramide\nDRUG 2 BACKGROUND INFORMATION: Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has general anticholinergic effects which contribute to unwanted adverse effects. Disopyramide is available in both oral and intravenous forms. In 1972, when it was one of the only alternatives to quinidine, it was praised for being more potent and somewhat less toxic. However, a 2012 review of antiarrhythmic drugs noted that disopyramide is among the most toxic agents, with a high burden of side effects and increased mortality (compared to placebo) when used to treat atrial fibrillation.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Paracetamol-erythema-Disopyramide"}]}}
{"custom_id": "Famotidine-Formoterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Formoterol\nDRUG 2 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-weight gain-Formoterol"}]}}
{"custom_id": "Repaglinide-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Repaglinide\nDRUG 1 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Repaglinide-nasal sinus congestion-Perindopril"}]}}
{"custom_id": "Zolpidem-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zolpidem\nDRUG 1 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zolpidem-Adenopathy-vincristine"}]}}
{"custom_id": "Dexpramipexole-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dexpramipexole\nDRUG 1 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 2 NAME: Ticlopidine\nDRUG 2 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-hyperglycaemia-Ticlopidine"}]}}
{"custom_id": "Fentanyl-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Zaleplon"}]}}
{"custom_id": "Carvedilol-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-belching-solifenacin"}]}}
{"custom_id": "Cimetidine-Sumatriptan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Sumatriptan\nDRUG 2 BACKGROUND INFORMATION: Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-angiitis-Sumatriptan"}]}}
{"custom_id": "Amlodipine-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-cholecystitis-Metolazone"}]}}
{"custom_id": "Ketorolac-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-back injury-Duloxetine"}]}}
{"custom_id": "Doxazosin-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol"}]}}
{"custom_id": "Haloperidol-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Haloperidol-apoplexy-oxybutynin"}]}}
{"custom_id": "Furosemide-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-apoplexy-Rosiglitazone"}]}}
{"custom_id": "Fentanyl-Ondansetron-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Ondansetron"}]}}
{"custom_id": "Methylphenidate-Modafinil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Modafinil\nDRUG 2 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-back injury-Modafinil"}]}}
{"custom_id": "Gabapentin-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-Dyspnea exertional-Bimatoprost"}]}}
{"custom_id": "Lidocaine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lidocaine-cholecystitis-Metoprolol"}]}}
{"custom_id": "Furosemide-Gemfibrozil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-gastric inflammation-Gemfibrozil"}]}}
{"custom_id": "Famotidine-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamivudine"}]}}
{"custom_id": "Naproxen-Brimonidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Brimonidine\nDRUG 2 BACKGROUND INFORMATION: Brimonidine is an \u03b12-adrenergic agonist exhibiting therapeutic efficacy in attenuating open-angle glaucoma and ocular hypertension via modulation of intraocular pressure through dual mechanisms: decreased aqueous humor synthesis and enhanced uveoscleral outflow. Additionally, its vasoconstrictive action on cutaneous vasculature imparts symptomatic relief in erythema associated with rosacea when administered topically. The pharmacological profile is complemented by its inclusion in a fixed-dose compound with timolol maleate, enhancing antihypertensive efficacy. Ocular administration predisposes patients to localized side effects such as conjunctival hyperemia, pruritus, and xerostomia, whereas dermal application manifests as erythema, discomfort, and potential cephalgia. While systemic absorption is minimal, hypersensitivity reactions and hypotensive episodes warrant clinical vigilance. Brimonidine's safety profile in gravid populations is reassuring, and its generically available formulations have solidified its position as a mainstay in ophthalmic and dermatologic therapeutics, underscored by a substantial prescription volume.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-apoplexy-Brimonidine"}]}}
{"custom_id": "Haloperidol-Rosiglitazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Haloperidol-insulin dependent diabetes mellitus-Rosiglitazone"}]}}
{"custom_id": "Famotidine-Exemestane-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Exemestane\nDRUG 2 BACKGROUND INFORMATION: Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-apoplexy-Exemestane"}]}}
{"custom_id": "Ciclopirox-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ciclopirox\nDRUG 1 BACKGROUND INFORMATION: Ciclopirox is a medication used for the treatment of moderate onychomycosis of fingernails and toenails, and for the treatment of seborrheic dermatitis.\nIn 2022, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ciclopirox-asthenia-Imatinib"}]}}
{"custom_id": "Ketoprofen-Sufentanil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Sufentanil\nDRUG 2 BACKGROUND INFORMATION: Sufentanil, sold under the brand names Sufenta among others, is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 to 1,000 times as potent as morphine. Structurally, sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring (which increases potency but is believed to reduce duration of action), and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-abnormal EEG-Sufentanil"}]}}
{"custom_id": "Naproxen-Cetirizine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Cetirizine\nDRUG 2 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Cetirizine"}]}}
{"custom_id": "vincristine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: vincristine\nDRUG 1 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): vincristine-drug toxicity NOS-Torasemide"}]}}
{"custom_id": "Lamotrigine-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-gastric inflammation-Dexpramipexole"}]}}
{"custom_id": "Candesartan-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-apoplexy-Dexpramipexole"}]}}
{"custom_id": "Temazepam-Zafirlukast-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Zafirlukast\nDRUG 2 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-dysarthria-Zafirlukast"}]}}
{"custom_id": "indometacin-Isoniazid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Isoniazid\nDRUG 2 BACKGROUND INFORMATION: Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-Adenopathy-Isoniazid"}]}}
{"custom_id": "Aciclovir-Azelastine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Azelastine\nDRUG 2 BACKGROUND INFORMATION: Azelastine functions as a second-generation H1 receptor antagonist with multifaceted applications, notably as a nasal spray for allergic rhinitis and ocular drops for allergic conjunctivitis, while also exhibiting utility in the management of asthma and dermal hypersensitivity reactions via oral administration. Its pharmacodynamics involve rapid onset, with ocular effects manifesting within minutes and intranasal effects appearing within an hour, sustained for up to 12 hours. This antihistaminic agent exerts its therapeutic efficacy by impeding the release of inflammatory mediators, prominently histamine, thus mitigating allergic symptomatology. The adverse effect profile includes cephalalgia, somnolence, dysgeusia, and pharyngitis, with its safety profile during gestation and lactation remaining ambiguous. Azelastine's widespread usage is reflected in its substantial prescription frequency, denoting its significance in the therapeutic landscape.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-erythema-Azelastine"}]}}
{"custom_id": "Ketorolac-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-cholecystitis-Trazodone"}]}}
{"custom_id": "Metolazone-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol"}]}}
{"custom_id": "Carvedilol-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-erythema-Metolazone"}]}}
{"custom_id": "Zafirlukast-Duloxetine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zafirlukast\nDRUG 1 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-loss of weight-Duloxetine"}]}}
{"custom_id": "Diazepam-melphalan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: melphalan\nDRUG 2 BACKGROUND INFORMATION: Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.\nCommon side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.\nMelphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Diazepam-bulging-melphalan"}]}}
{"custom_id": "Celecoxib-Lamotrigine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-erythema-Lamotrigine"}]}}
{"custom_id": "Furosemide-Indapamide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Indapamide\nDRUG 2 BACKGROUND INFORMATION: Indapamide, a thiazide-like sulfonamide diuretic, is employed primarily in mitigating hypertension and addressing decompensated heart failure, functioning by inhibiting sodium reabsorption at the distal convoluted tubule, which consequently enhances renal excretion of sodium and water, thereby reducing plasma volume and vascular resistance. Its efficacy parallels that of traditional thiazide diuretics and, in combination with perindopril, exerts an enhanced antihypertensive synergy. Indapamide demonstrates a favorable cardiovascular profile, attenuating risks associated with major events and heart failure in hypertensive cohorts, akin to chlorthalidone, and shows superior outcomes compared to hydrochlorothiazide. Moreover, both thiazide and thiazide-like diuretics effectively minimize stroke incidence, maintaining safety profiles comparable to other antihypertensive classes such as angiotensin II receptor antagonists and dihydropyridine calcium antagonists, while exhibiting a diminished spectrum of adverse effects relative to ACE inhibitors and non-dihydropyridine calcium blockers, thus occupying a critical niche in essential therapeutic regimens.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-Adenopathy-Indapamide"}]}}
{"custom_id": "Citalopram-Dapsone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-Adenopathy-Dapsone"}]}}
{"custom_id": "Gabapentin-Minoxidil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Minoxidil\nDRUG 2 BACKGROUND INFORMATION: Minoxidil  is a medication used for the treatment of high blood pressure and pattern hair loss. It is an antihypertensive and a vasodilator. It is available as a generic medication by prescription in oral tablet form and over-the-counter as a topical liquid or foam.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-insulin dependent diabetes mellitus-Minoxidil"}]}}
{"custom_id": "Orphenadrine-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Orphenadrine\nDRUG 1 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Trazodone"}]}}
{"custom_id": "Ketorolac-Moexipril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Moexipril\nDRUG 2 BACKGROUND INFORMATION: Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. \nIt works by inhibiting the conversion of angiotensin I to angiotensin II. \nIt was patented in 1980 and approved for medical use in 1995. Moexipril is available from Schwarz Pharma under the trade name Univasc.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketorolac-nausea-Moexipril"}]}}
{"custom_id": "Naproxen-Exemestane-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Exemestane\nDRUG 2 BACKGROUND INFORMATION: Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-Exemestane"}]}}
{"custom_id": "Fentanyl-Loxapine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Loxapine\nDRUG 2 BACKGROUND INFORMATION: Loxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia. The medicine is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.\nLoxapine may be metabolized by N-demethylation to amoxapine, a tricyclic antidepressant.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fentanyl-deglutition disorder-Loxapine"}]}}
{"custom_id": "Tolbutamide-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tolbutamide\nDRUG 1 BACKGROUND INFORMATION: Tolbutamide is a first-generation potassium channel blocker, sulfonylurea oral hypoglycemic medication. This drug may be used in the management of type 2 diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas.\nIt is not routinely used due to a higher incidence of adverse effects compared to newer, second-generation sulfonylureas, such as Glibenclamide. It generally has a short duration of action due to its rapid metabolism, so is safe for use in older people.\nIt was discovered in 1956.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Tolbutamide-muscle disorder-Perindopril"}]}}
{"custom_id": "Efavirenz-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Efavirenz\nDRUG 1 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Efavirenz-gastric inflammation-Lamivudine"}]}}
{"custom_id": "Dapsone-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dapsone\nDRUG 1 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dapsone-acute kidney failure-Perindopril"}]}}
{"custom_id": "Candesartan-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-apoplexy-Desloratadine"}]}}
{"custom_id": "Furosemide-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-loss of weight-Sorafenib"}]}}
{"custom_id": "Megestrol-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Megestrol\nDRUG 1 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Megestrol-loss of weight-Desloratadine"}]}}
{"custom_id": "Metronidazole-Repaglinide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Repaglinide\nDRUG 2 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-erythema-Repaglinide"}]}}
{"custom_id": "Naproxen-Orphenadrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Orphenadrine\nDRUG 2 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Orphenadrine"}]}}
{"custom_id": "Triazolam-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Triazolam\nDRUG 1 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG 2 NAME: Zaleplon\nDRUG 2 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Triazolam-deglutition disorder-Zaleplon"}]}}
{"custom_id": "Naproxen-Carvedilol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Carvedilol\nDRUG 2 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Carvedilol"}]}}
{"custom_id": "Alprazolam-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Sorafenib\nDRUG 2 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Alprazolam-thrombocytopenia-Sorafenib"}]}}
{"custom_id": "Cimetidine-Ibuprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Ibuprofen"}]}}
{"custom_id": "Famotidine-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Imatinib\nDRUG 2 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-erythema-Imatinib"}]}}
{"custom_id": "Aciclovir-Efavirenz-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Aciclovir-cholecystitis-Efavirenz"}]}}
{"custom_id": "Ondansetron-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-methaemoglobinaemia-Zolpidem"}]}}
{"custom_id": "Amlodipine-melphalan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: melphalan\nDRUG 2 BACKGROUND INFORMATION: Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.\nCommon side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.\nMelphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-periodontitis-melphalan"}]}}
{"custom_id": "Naproxen-Efavirenz-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Efavirenz"}]}}
{"custom_id": "Capecitabine-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Capecitabine\nDRUG 1 BACKGROUND INFORMATION: Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.\nCommon side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.\nCapecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Capecitabine-drug toxicity NOS-Desloratadine"}]}}
{"custom_id": "Famotidine-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-loss of weight-Darunavir"}]}}
{"custom_id": "Ofloxacin-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ofloxacin\nDRUG 1 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-gastric inflammation-Oxaprozin"}]}}
{"custom_id": "Citalopram-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Salmeterol\nDRUG 2 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Salmeterol"}]}}
{"custom_id": "Orphenadrine-Temazepam-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Orphenadrine\nDRUG 1 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Temazepam"}]}}
{"custom_id": "acetazolamide-Lamotrigine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-hiccough-Lamotrigine"}]}}
{"custom_id": "Telmisartan-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Telmisartan\nDRUG 1 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Telmisartan-dysarthria-solifenacin"}]}}
{"custom_id": "Temazepam-Emtricitabine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Emtricitabine\nDRUG 2 BACKGROUND INFORMATION: Emtricitabine (FTC; 2',3'-dideoxy-5-fluoro-3'-thiacytidine) operates as a potent nucleoside reverse-transcriptase inhibitor (NRTI) indicated for both prophylaxis and active management of HIV infection across diverse age cohorts. This molecule is integral to the composition of the Quad pill, specifically Stribild and Genvoya, and is prominently featured in fixed-dose co-formulations with tenofovir disoproxil as Truvada and with tenofovir alafenamide as Descovy, underscoring its critical role in multi-drug regimens. Emtricitabine's strategic inclusion in these combinations has earned it placement on the WHO's List of Essential Medicines, reflecting its indispensable utility in comprehensive antiretroviral therapy. Notably, the FDA-approved fixed-dose triple combination incorporating emtricitabine, tenofovir, and efavirenz, commercially available as Atripla, exemplifies its integration into optimized antiretroviral protocols aimed at maximizing therapeutic efficacy and medication adherence.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-heart rate increased-Emtricitabine"}]}}
{"custom_id": "Metoprolol-Acitretin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metoprolol\nDRUG 1 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 2 NAME: Acitretin\nDRUG 2 BACKGROUND INFORMATION: Acitretin, sold under the brand names Neotigason and Soriatane, is a second-generation retinoid. It is taken orally, and is typically used for psoriasis.\nAcitretin is an oral retinoid used in the treatment of severe resistant psoriasis. Because of the potential for problems and severe side effects it is generally used in only very severe cases of psoriasis that have been unresponsive to other treatments.  It binds to nuclear receptors that regulates gene transcription.  They induce keratinocyte differentiation and reduce epidermal hyperplasia, leading to the slowing of cell reproduction.  Acitretin is readily absorbed and widely distributed after oral administration.  A therapeutic effect occurs after two to four weeks or longer.\nPatients who have received the medication are advised against giving blood for at least three years due to the risk of birth defects.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metoprolol-loss of weight-Acitretin"}]}}
{"custom_id": "Candesartan-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Candesartan-cholecystitis-Lamivudine"}]}}
{"custom_id": "Gabapentin-Amiloride-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Amiloride\nDRUG 2 BACKGROUND INFORMATION: Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-weight gain-Amiloride"}]}}
{"custom_id": "Carvedilol-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Pirbuterol\nDRUG 2 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-weight gain-Pirbuterol"}]}}
{"custom_id": "Dexpramipexole-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dexpramipexole\nDRUG 1 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 2 NAME: Trimethoprim\nDRUG 2 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-weight gain-Trimethoprim"}]}}
{"custom_id": "Metolazone-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metolazone-loss of weight-Dexpramipexole"}]}}
{"custom_id": "Amlodipine-Ketoprofen-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Ketoprofen\nDRUG 2 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-gastric inflammation-Ketoprofen"}]}}
{"custom_id": "Gabapentin-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Gabapentin-cholecystitis-Darunavir"}]}}
{"custom_id": "Naproxen-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Zolpidem"}]}}
{"custom_id": "acetazolamide-Haloperidol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Haloperidol\nDRUG 2 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): acetazolamide-confusion-Haloperidol"}]}}
{"custom_id": "indometacin-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): indometacin-apoplexy-Sildenafil"}]}}
{"custom_id": "Zolpidem-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zolpidem\nDRUG 1 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-Perindopril"}]}}
{"custom_id": "Ondansetron-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ondansetron\nDRUG 1 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 2 NAME: Trazodone\nDRUG 2 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ondansetron-hepatic neoplasia-Trazodone"}]}}
{"custom_id": "Naproxen-Doxazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-back injury-Doxazosin"}]}}
{"custom_id": "Ketoprofen-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-High blood pressure-Perindopril"}]}}
{"custom_id": "Dipyridamole-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Dipyridamole\nDRUG 1 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Dipyridamole-apoplexy-oxybutynin"}]}}
{"custom_id": "Lamotrigine-Amiloride-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Amiloride\nDRUG 2 BACKGROUND INFORMATION: Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-weight gain-Amiloride"}]}}
{"custom_id": "Sumatriptan-Balsalazide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Sumatriptan\nDRUG 1 BACKGROUND INFORMATION: Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.\n\nDRUG 2 NAME: Balsalazide\nDRUG 2 BACKGROUND INFORMATION: Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.\nIt is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. It is in the category of disease-modifying antirheumatic drugs (DMARDs) family of medications. It is unclear exactly how it works.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Sumatriptan-Difficulty breathing-Balsalazide"}]}}
{"custom_id": "Temazepam-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-abnormal ECG-Bimatoprost"}]}}
{"custom_id": "Doxazosin-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Doxazosin-apoplexy-Dexpramipexole"}]}}
{"custom_id": "Telmisartan-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Telmisartan\nDRUG 1 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG 2 NAME: Bimatoprost\nDRUG 2 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Telmisartan-High blood pressure-Bimatoprost"}]}}
{"custom_id": "Amlodipine-Sufentanil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Sufentanil\nDRUG 2 BACKGROUND INFORMATION: Sufentanil, sold under the brand names Sufenta among others, is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 to 1,000 times as potent as morphine. Structurally, sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring (which increases potency but is believed to reduce duration of action), and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-right heart failure-Sufentanil"}]}}
{"custom_id": "Ibuprofen-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Perindopril\nDRUG 2 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-gastric inflammation-Perindopril"}]}}
{"custom_id": "Zafirlukast-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zafirlukast\nDRUG 1 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-erythema-Zolpidem"}]}}
{"custom_id": "Ranitidine-Adapalene-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ranitidine\nDRUG 1 BACKGROUND INFORMATION: Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.\n\nDRUG 2 NAME: Adapalene\nDRUG 2 BACKGROUND INFORMATION: Adapalene, sold under the brand name Differin among others, is a third-generation topical retinoid primarily used in the treatment of mild-moderate acne, and is also used off-label to treat keratosis pilaris as well as other skin conditions. Studies have found adapalene is as effective as other retinoids, while causing less irritation. It also has several advantages over other retinoids. The adapalene molecule is more stable compared to tretinoin and tazarotene, which leads to less concern for photodegradation. It is also chemically more stable compared to the other two retinoids, allowing it to be used in combination with benzoyl peroxide. Due to its effects on keratinocyte proliferation and differentiation, adapalene is superior to tretinoin for the treatment of comedonal acne and is often used as a first-line agent. The Swiss company Galderma developed adapalene.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Ranitidine-gastric inflammation-Adapalene"}]}}
{"custom_id": "Amlodipine-Metronidazole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Metronidazole\nDRUG 2 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-cholecystitis-Metronidazole"}]}}
{"custom_id": "Naproxen-Risedronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Risedronic acid\nDRUG 2 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-erythema-Risedronic acid"}]}}
{"custom_id": "Metronidazole-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Fosphenytoin\nDRUG 2 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Metronidazole-trigeminal neuralgia-Fosphenytoin"}]}}
{"custom_id": "Temazepam-Bosentan-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Bosentan\nDRUG 2 BACKGROUND INFORMATION: Bosentan, sold under the brand name Tracleer among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH).\nBosentan is available as film-coated tablets (62.5 mg or 125 mg) or as dispersable tablets for oral suspension (32 mg).\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Temazepam-subarachnoid haemorrhage-Bosentan"}]}}
{"custom_id": "Pyridostigmine-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Pyridostigmine\nDRUG 1 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG 2 NAME: Telithromycin\nDRUG 2 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Pyridostigmine-dysarthria-Telithromycin"}]}}
{"custom_id": "Lamotrigine-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-Cystitis Interstitial-Zolpidem"}]}}
{"custom_id": "Lamotrigine-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Fosphenytoin\nDRUG 2 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-bradycardia-Fosphenytoin"}]}}
{"custom_id": "Brimonidine-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Brimonidine\nDRUG 1 BACKGROUND INFORMATION: Brimonidine is an \u03b12-adrenergic agonist exhibiting therapeutic efficacy in attenuating open-angle glaucoma and ocular hypertension via modulation of intraocular pressure through dual mechanisms: decreased aqueous humor synthesis and enhanced uveoscleral outflow. Additionally, its vasoconstrictive action on cutaneous vasculature imparts symptomatic relief in erythema associated with rosacea when administered topically. The pharmacological profile is complemented by its inclusion in a fixed-dose compound with timolol maleate, enhancing antihypertensive efficacy. Ocular administration predisposes patients to localized side effects such as conjunctival hyperemia, pruritus, and xerostomia, whereas dermal application manifests as erythema, discomfort, and potential cephalgia. While systemic absorption is minimal, hypersensitivity reactions and hypotensive episodes warrant clinical vigilance. Brimonidine's safety profile in gravid populations is reassuring, and its generically available formulations have solidified its position as a mainstay in ophthalmic and dermatologic therapeutics, underscored by a substantial prescription volume.\n\nDRUG 2 NAME: Terazosin\nDRUG 2 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Brimonidine-weight gain-Terazosin"}]}}
{"custom_id": "Fluorouracil-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fluorouracil\nDRUG 1 BACKGROUND INFORMATION: Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.\n\nDRUG 2 NAME: Fulvestrant\nDRUG 2 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Fluorouracil-loss of weight-Fulvestrant"}]}}
{"custom_id": "Naproxen-Gabapentin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Gabapentin\nDRUG 2 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-Gabapentin"}]}}
{"custom_id": "alendronic acid-Efavirenz-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Efavirenz"}]}}
{"custom_id": "Carvedilol-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Darunavir\nDRUG 2 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Carvedilol-coughing blood-Darunavir"}]}}
{"custom_id": "Triazolam-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Triazolam\nDRUG 1 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG 2 NAME: solifenacin\nDRUG 2 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Triazolam-increased white blood cell count-solifenacin"}]}}
{"custom_id": "Furosemide-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Furosemide-fracture nonunion-Zolpidem"}]}}
{"custom_id": "Famotidine-Pilocarpine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Pilocarpine\nDRUG 2 BACKGROUND INFORMATION: Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Famotidine-deglutition disorder-Pilocarpine"}]}}
{"custom_id": "Theophylline-Bumetanide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Theophylline\nDRUG 1 BACKGROUND INFORMATION: Theophylline, also known as 1,3-dimethylxanthine, is a drug that inhibits phosphodiesterase and blocks adenosine receptors. It is used to treat chronic obstructive pulmonary disease (COPD) and asthma. Its pharmacology is similar to other methylxanthine drugs (e.g., theobromine and caffeine). Trace amounts of theophylline are naturally present in tea, coffee, chocolate, yerba mat\u00e9, guarana, and kola nut.\nThe name 'theophylline' derives from \"Thea\"\u2014the former genus name for tea + Legacy Greek \u03c6\u03cd\u03bb\u03bb\u03bf\u03bd (ph\u00fallon, \"leaf\") + -ine.\n\nDRUG 2 NAME: Bumetanide\nDRUG 2 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Theophylline-abnormal ECG-Bumetanide"}]}}
{"custom_id": "Celecoxib-Labetalol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Back Ache-Labetalol"}]}}
{"custom_id": "Risedronic acid-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Torasemide\nDRUG 2 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-gastric inflammation-Torasemide"}]}}
{"custom_id": "Amlodipine-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant tasked with generating one question about a drug-drug interaction (DDI) based on background information about two drugs and a knowledge-graph triple describing their interaction (subject-predicate-object format).\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of both drugs and their relationship. The answer must be either Drug 1 or Drug 2.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about either drug.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG-DRUG INTERACTION TRIPLE (subject-predicate-object): Amlodipine-myelodysplasia-Desloratadine"}]}}
